



Christian Brander

Generated from: Editor CVN de FECYT

Date of document: 15/02/2024

v 1.4.3

3cda2cdf20a29b46fd991296275f2fb5

This electronic file (PDF) has embedded CVN technology (CVN-XML). The CVN technology of this file allows you to export and import curricular data from and to any compatible data base. List of adapted databases available at: <http://cvn.fecyt.es/>



Summary of CV

This section describes briefly a summary of your career in science, academic and research; the main scientific and technological achievements and goals in your line of research in the medium -and long- term. It also includes other important aspects or peculiarities.

Dr. Brander is a cellular immunologist with extensive experience in the study of T cell responses to viral infections, including HIV, Hepatitis- and Herpes-viruses in the setting of HIV co-infection, lymphoproliferative disorders and in solid organ transplanted hosts. He has a long track record of assessing cellular immune responses to HIV infection in particular and has provided some of the largest data sets existing on T cell activity to HIV and its relevance for relative HIV control. He acts as a curator of the immunology database section of the renowned HIV-database at the Los Alamos National Laboratories and has helped establish the most detailed immune epitope landscape of any known human pathogen. He has also investigated the cellular immunity to hepatitis- and herpesviruses, making seminal contributions to the better understanding of host immunity to these pathogens in different clinical settings. More recently, he has established some of the necessary tools to study host immunity to SARS-CoV-2 and developed in vitro test system that allow to measure virus-specific T cell immunity as a prognostic tool for Covid19 disease evolution.

Over the last years he has focused his attention increasingly on the epigenetic mechanisms that control the host immunity to these pathogens and how viral infection can impact the pre-existing immunity to co-pathogens. These studies are especially relevant in the cancer setting where Dr. Brander's work has shown infections such as HIV to profoundly impact the pre-existing cellular immunity to EBV and other cancer-driving herpesviruses (e.g. KSHV).

He has published more than 300 peer-reviewed articles and 15 book chapters, of which more than 150 were published during the last 10 years, with more than 90% in first quartile journals. He has been cited more than 30,000 times and has a H-factor of 90.



General quality indicators of scientific research

This section describes briefly the main quality indicators of scientific production (periods of research activity, experience in supervising doctoral theses, total citations, articles in journals of the first quartile, H index...). It also includes other important aspects or peculiarities.

Total cite number: 30214(Google Scholar)
Cites/year the last 10 years: 1372/year (Google Scholar)
Publications in the first quartile (Q1): 254 out of 298 total
Indice h: 90 (Google Scholar)

**Christian Brander**

Surname(s): **Brander**
 Name: **Christian**
 NIE: **X9971720R**
 ORCID: **0000-0002-0548-5778**
 ScopusID: **26643182400**
 Date of birth: **18/10/1967**
 Gender: **Male**
 Nationality: **Switzerland**
 Country of birth: **Switzerland**
 Contact province: **Barcelona**
 City of birth: **Olten**
 Contact address: **Instituto de Investigación del Sida IrsiCaixa**
 Rest of contact address: **Hospital Germans Trias i Pujol. Ctra. de Canyet s/n**
 Postcode: **08916**
 Contact country: **Spain**
 Contact aut. region/reg.: **Catalonia**
 Contact city: **Badalona**
 Land line phone: **(34) 934656374 - 166**
 Fax: **(34) 934653968**
 Email: **cbrander@irsicaixa.es**

Current professional situation

Employing entity: Institut de Recerca de la Sida **Type of entity:** Foundation IrsiCaixa

Department: Hospital Universitari Germans Trias i Pujol

Professional category: Senior Research Professor, ICREA

Start date: 01/08/2008

Type of contract: Permanent employment contract **Dedication regime:** Full time

Primary (UNESCO code): 241200 - Immunology

Employing entity: FUND. PRIVADA INST, DE INVESTIGACION DE LA SIDA-CAIXA **Type of entity:** Foundation

Department: Host Genetics and Cellular Immunity, Department Inmunidad Celular y Genética del huésped

Professional category: Senior Research Professor

Phone: 934656374

Start date: 14/07/2008

Type of contract: Permanent employment contract **Dedication regime:** Full time

Primary (UNESCO code): 241200 - Immunology

Secondary (UNESCO code): 242000 - Virology

Tertiary (UNESCO code): 241210 - Vaccines

Identify key words: Neurophysiology; Molecular mechanism of disease; Genetics expresión of regulations; Virology

Previous positions and activities

	Employing entity	Professional category	Start date
1	Harvard Medical School	Associate Professor of Medicine	2006
2	Partners AIDS Research Center, Mass. General Hospital	Assistant Immunologist	2006
3	Harvard Medical School	Assistant Professor of Medicine	2002
4	Partners AIDS Research Center, Mass. General Hospital	Assistant in Immunology	1998
5	Harvard Medical School	Instructor in Medicine	1998
6	Massachusetts General Hospital	Research Fellow, Infectious Diseases	1995
7	Inselspital, Berne, Switzerland	Research Fellow, Clinical Immunology	1994

- 1** **Employing entity:** Harvard Medical School **Type of entity:** University
Professional category: Associate Professor of Medicine
Start-End date: 2006 - 2011 **Duration:** 5 years
- 2** **Employing entity:** Partners AIDS Research Center, Mass. General Hospital **Type of entity:** R&D Centre
Professional category: Assistant Immunologist
Start-End date: 2006 - 2011 **Duration:** 5 years
- 3** **Employing entity:** Harvard Medical School **Type of entity:** University
Professional category: Assistant Professor of Medicine
Start-End date: 2002 - 2006 **Duration:** 4 years
- 4** **Employing entity:** Partners AIDS Research Center, Mass. General Hospital **Type of entity:** R&D Centre
Professional category: Assistant in Immunology
Start-End date: 1998 - 2006 **Duration:** 8 years
- 5** **Employing entity:** Harvard Medical School **Type of entity:** University
Professional category: Instructor in Medicine
Start-End date: 1998 - 2002 **Duration:** 4 years
- 6** **Employing entity:** Massachusetts General Hospital **Type of entity:** Healthcare Institutions
Professional category: Research Fellow, Infectious Diseases
Start-End date: 1995 - 1998 **Duration:** 3 years
- 7** **Employing entity:** Inselspital, Berne, Switzerland **Type of entity:** Healthcare Institutions
Professional category: Research Fellow, Clinical Immunology
Start-End date: 1994 - 1995 **Duration:** 1 year



Education

University education

1st and 2nd cycle studies and pre-Bologna degrees

1 **University degree:** Higher degree

Name of qualification: MS, Diploma in Medical Microbiology

Degree awarding entity: University of Berne,
Switzerland

Type of entity: University

Date of qualification: 1991

2 **University degree:** Higher degree

Name of qualification: BS

Degree awarding entity: Kantonsschule Olten
(Grammar School of Science and Mathematics)

Type of entity: Escuela Cantonal

Date of qualification: 1986

Doctorates

Doctorate programme: PhD in Immunology

Degree awarding entity: University of Berne,
Switzerland

Type of entity: University

Date of degree: 1994

Language skills

Language	Listening skills	Reading skills	Spoken interaction	Speaking skills	Writing skills
Catalan		C1	A1	A1	A1
German		C1	C1	C1	C1
Spanish		C1	C1	C1	C1
French		C1	C1	C1	C1
English		C1	C1	C1	C1

Teaching experience



Experience supervising doctoral thesis and/or final year projects

- 1** **Project title:** Proteomics analysis for the identification of biomarkers and potential therapeutic targets for HIV-1 control and HIV-related neurological dysfunction
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Clara Duran-Castells
Date of reading: 2023
- 2** **Project title:** Alternative components of the cellular immunity to SARS-CoV-2 and HIV infection: beyond the classical CTL
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Luis Romero-Martin
Date of reading: 2022
- 3** **Project title:** Systems Biology for the identification of epigenetic biomarkers and host factors associated with HIV-1 control
Co-director of thesis: Marta Ruiz-Riol
Entity: Universitat Autònoma de Barcelona
Student: Bruna Oriol-Tordera
Obtained qualification: Excellent Cum Laude
Date of reading: 09/12/2021
Date of award: 09/12/2021
- 4** **Project title:** Challenges and prospects for an immune-driven functional cure of HIV infection
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Miriam Rosas Umbert
Date of reading: 12/11/2019
- 5** **Project title:** Application of systems biology to the identification of epigenetically regulated host markers associated with HIV control
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Bruna Oriol Tordera
Date of reading: 2018
- 6** **Project title:** The role of HLA-E expression profiles in the in vivo control of HIV
Entity: Universitat de Vic **Type of entity:** University
Student: Clara Duran Castells
Date of reading: 2017
- 7** **Project title:** Cambios en el Grado de Metilación a nivel del DNA con Repercusiones en la Expresión de Proteínas debido a la Infección por VIH para un posible control de la Infección.
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Jesus Poch Coronel
Date of reading: 2016
- 8** **Project title:** Exploring HLA-II associations with HIV disease progression markers
Entity: Universitat de Vic
Student: Bruna Oriol Tordera
Date of reading: 2016



- 9** **Project title:** Assessment of immunogenicity of HIVconsv vaccination in a cohort of early treated HIV-1 infected population
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Alvaro Sanchez Bernabeu
Date of reading: 2015
- 10** **Project title:** Combined biostatistics and bioinformatics analyses to identify epigenetically regulated host factors associated with control of HIV disease progression
Entity: Universitat de Vic
Student: Laura Ordeig Gaja
Date of reading: 2015
- 11** **Project title:** Study of a cohort of elite and viremic controllers
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Muntsa Rocafort Junca
Date of reading: 2013
- 12** **Project title:** Effect of viral fitness on the immune profiles of the HIV-specific cellular immune response
Entity: University of Konstanz (Germany)
Student: Benjamin Spreng
Date of reading: 2013
- 13** **Project title:** Rational Design and testing of Novel HIV T cell immunogens
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Beatriz Mothe
Date of reading: 2012
- 14** **Project title:** Kinetics of Cytotoxic T-Lymphocyte Responses in HIV and EBV Infection and its Physiological Relevance
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Beatriz Mothe Pujadas
Date of reading: 2009
- 15** **Project title:** HCV epitome: a novel Approach to design highly immunogenic sequences in a highly heterogenic Virus
Entity: University of Bern **Type of entity:** University
Student: Daniel Yerly
Date of reading: 2006
- 16** **Project title:** Antigen Processing and Presentation in Primary Effusion Lymphoma
Entity: Harvard University **Type of entity:** University
Student: Todd Suscovich
Date of reading: 2005
- 17** **Project title:** Understanding HIV Diversity: Impact on vaccine development and treatment options
Entity: Universitat Autònoma de Barcelona **Type of entity:** University
Student: Susana Perez Alvarez



Healthcare experience

Other activities/achievements not included above

- 1** **Other relevant activities:** Scholar Award for Best Abstract; 30th Annual Meeting of the American Society for Histocompatibility and Immunogenetics.
Entity where project took place: American Society for Histocompatibility and Immunogenetics. **Type of entity:** Associations and Groups
End date: 2004
- 2** **Other relevant activities:** Advanced Scientist Award
Entity where project took place: Swiss National Science Foundation **Type of entity:** Foundation
End date: 1996
- 3** **Other relevant activities:** Young Investigator Award
Entity where project took place: Swiss National Science Foundation **Type of entity:** Foundation
End date: 1995
- 4** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Antiviral Research **Type of entity:** Publication
- 5** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Cell Host Microbe **Type of entity:** Publication
- 6** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: AIDS **Type of entity:** Publication
- 7** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Antiviral Therapy **Type of entity:** Publication
- 8** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Blood **Type of entity:** Publication
- 9** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Clinical and Experimental Immunology **Type of entity:** Publication
- 10** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Infection, Genetics and Evolution **Type of entity:** Publication



- 11** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: International Journal of Infectious Diseases **Type of entity:** Publication
- 12** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: JAMA **Type of entity:** Publication
- 13** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Journal of AIDS **Type of entity:** Publication
- 14** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Journal of Clinical Investigation **Type of entity:** Publication
- 15** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Journal of Immunological Methods **Type of entity:** Publication
- 16** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Journal of Immunology **Type of entity:** Publication
- 17** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Journal of Infectious Diseases **Type of entity:** Publication
- 18** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Journal of Virology **Type of entity:** Publication
- 19** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Mayo Clinic Proceedings **Type of entity:** Publication
- 20** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Nature Medicine **Type of entity:** Publication
- 21** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Nature **Type of entity:** Publication
- 22** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Public Library of Science (PLOS) Pathogen **Type of entity:** Publication
- 23** **Other relevant activities:** Ad-hoc Reviewer
Entity where project took place: Transplant Infectious Disease **Type of entity:** Publication



- 24 Other relevant activities:** Co-Editor
Entity where project took place: Journal of Visualized Experiments **Type of entity:** Publication
- 25 Other relevant activities:** Deputy Editor
Entity where project took place: Journal of Translational Medicine **Type of entity:** Publication
- 26 Other relevant activities:** Editor
Entity where project took place: Los Alamos National Laboratory, HIV Molecular Immunology Database **Type of entity:** R&D Centre
- 27 Other relevant activities:** Editorial Board
Entity where project took place: Annal of Translational Medicine
- 28 Other relevant activities:** Editorial Board
Entity where project took place: Journal of Immunotherapy **Type of entity:** Publication

Scientific and technological experience

Scientific or technological activities

R&D projects funded through competitive calls of public or private entities

- 1 Name of the project:** Multi-omic understanding of the transformed host T-cell response to HIV following therapeutic vaccination
Entity where project took place: University of California Davis **Type of entity:** University
City of entity: Davis, United States of America
Name principal investigator (PI, Co-PI....): Christian Brander
Nº of researchers: 12
Funding entity or bodies: NIH **Type of entity:** State agency
City funding entity: Washington, United States of America
Start-End date: 01/06/2023 - 31/05/2028
Total amount: 7.744.672 €
- 2 Name of the project:** Epigenetic regulation of host factors in viral infections
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DEL SIDA-CAIXA
City of entity: Badalona, Catalonia, Spain
Name principal investigator (PI, Co-PI....): Christian Brander
Nº of researchers: 23
Funding entity or bodies: European Commission, HORIZIN Europe Program
City funding entity: Brussels, Belgium
Start-End date: 01/10/2022 - 30/09/2027



Total amount: 6.932.308 €

- 3** **Name of the project:** HIV Immunology database
Entity where project took place: Los Alamos National Laboratories EEUU
Type of participation: Co-ordinator
Start-End date: 16/12/2021 - 31/12/2026
Total amount: 125.000 €
- 4** **Name of the project:** Epigenetic regulation of host immunity and neurological long-term consequences of SARS-CoV-2 infection
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DEL SIDA-CAIXA
City of entity: Badalona, Catalonia, Spain
Name principal investigator (PI, Co-PI....): Christian Brander
Nº of researchers: 12
Funding entity or bodies:
Obra Social Fundación la Caixa **Type of entity:** Foundation
Start-End date: 01/11/2022 - 31/10/2025
Total amount: 999.580 €
- 5** **Name of the project:** Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
City of entity: badalona, Catalonia, Spain
Nº of researchers: 30
Type of participation: Principal investigator
Start-End date: 01/01/2020 - 30/06/2025
Total amount: 10.000.000 €
- 6** **Name of the project:** Boosted Flow Cytometry as a Diagnostic and Monitoring Tool for Virus/Pathogen specific T-Cell immune Profiles in HIV, TB and COVID Diseases
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DEL SIDA-CAIXA
Funding entity or bodies:
Obra Social Fundación la Caixa **Type of entity:** Foundation
Type of participation: Team member
Start-End date: 01/01/2022 - 31/12/2024
Total amount: 70.000 €
- 7** **Name of the project:** The epigenetic cascade of neurotropic viral infections (NEUROEpiCas)
Degree of contribution: Coordinator of total project, network or consortium
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA de investigación del sida
Funding entity or bodies:
Ministerio de Ciencia, Innovación y Universidades (MICINN)
Type of participation: Co-ordinator
Code according to the funding entity: PID2020-119710RB-I00
Start-End date: 01/09/2021 - 31/08/2024
Total amount: 205.700 €



- 8** **Name of the project:** RBDCOV: RBD Dimer recombinant protein vaccine against SARSCoV2
Entity where project took place: FUND. PRIVADA INSTITUTI DE INVESTIGACIÓN DEL SIDA-CAIXA
Funding entity or bodies:
Comisión Europea **Type of entity:** HEurope
Type of participation: Principal investigator
Start-End date: 01/12/2021 - 31/05/2024
Total amount: 9.779.211,25 € **Sub-project amount:** 1.596.520 €
- 9** **Name of the project:** Towards a universal therapeutic vaccine against chronic virus infections
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
City of entity: Badalona, Catalonia, Spain
Nº of researchers: 7
Type of participation: Principal investigator
Start-End date: 01/01/2019 - 05/11/2022
Total amount: 455.000 €
- 10** **Name of the project:** Role of reservoir composition and T cell immunity in HIV rebound kinetics
Entity where project took place: University of California Davis
Nº of researchers: 8
Type of participation: Principal investigator
Start-End date: 30/11/2017 - 30/06/2022
Total amount: 1.221.682 €
- 11** **Name of the project:** Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection (HIVACAR)
Entity where project took place: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Nº of researchers: 8
Start-End date: 01/01/2017 - 30/06/2022
- 12** **Name of the project:** European AIDS Vaccine Initiative 2020 - EAVI2020
Type of project: Demonstration, pilot projects, conceptual formulations and design of processes and services **Geographical area:** European Union
Degree of contribution: Scientific coordinator
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
City of entity: Badalona, Catalonia, Spain
Nº of researchers: 45
Funding entity or bodies:
Comisión Europea **Type of entity:** Entidad Pública
City funding entity: Madrid, Community of Madrid, Spain
Type of participation: Principal investigator
Code according to the funding entity: 681137
Start-End date: 01/11/2015 - 30/04/2022 **Duration:** 60 months
Total amount: 22.948.022,25 €
- 13** **Name of the project:** HIV Immunology database
Entity where project took place: Los Alamos National Laboratories EEUU
Start-End date: 2014 - 31/12/2021



- 14** **Name of the project:** Novel HIV therapeutic Vaccine Development “NUVATERA”
Entity where project took place: Aelix Therapeutics, S.L.
Funding entity or bodies:
CENTRO DE ACUSTICA APLICADA Y EVALUACION NO DESTRUCTIVA **Type of entity:** Associations and Groups
Ministerio de Ciencia e Innovación **Type of entity:** Body, others
Type of participation: Principal investigator
Code according to the funding entity: RTC-2017-6473-1.
Start-End date: 01/01/2018 - 30/06/2021
Total amount: 496.300 €
- 15** **Name of the project:** Identification of biomarkers predictive of HIV reservoir and neurocognitive impairment using integrated –omic approaches
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Nº of researchers: 8
Start-End date: 01/01/2018 - 31/12/2020
Total amount: 168.400 €
- 16** **Name of the project:** Therapeutic TriMix I mRNA based Vaccine in Chronic HIV -1 Infected Patients Receiving Antiretroviral Therapy
Entity where project took place: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
City of entity: Barcelona,
Name principal investigator (PI, Co-PI....): Felipe Garcia
Nº of researchers: 20
Funding entity or bodies:
Comisión Europea **Type of entity:** Organismo Publico
City funding entity: Madrid, Community of Madrid, Spain
Start-End date: 2013 - 30/11/2017
Total amount: 5.984.720 €
- 17** **Name of the project:** Influence of genetic, virologic and immunologic factors on outcomes of HCV/HIV OLT
Entity where project took place: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
City of entity: Barcelona, Catalonia, Spain
Name principal investigator (PI, Co-PI....): Jose Maria Mirò
Nº of researchers: 4
Funding entity or bodies:
The Roche Organ Transplantation Research Foundation **Type of entity:** Foundation
Start-End date: 2013 - 30/11/2016
Total amount: 100.000 €
- 18** **Name of the project:** Identification of "Communicome" profiles associated with control of HIV infection
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Name principal investigator (PI, Co-PI....): C Brander
Nº of researchers: 1
Funding entity or bodies:
Ministerio de Ciencia e Innovación. Investigación **Type of entity:** Estamento gubernamental
City funding entity: Madrid, Community of Madrid, Spain



Start-End date: 2013 - 2016

- 19 Name of the project:** Programa HIVACAT para el desarrollo de vacunas preventivas y terapéuticas frente al VIH
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
City of entity: Badalona, Catalonia, Spain
Start-End date: 2012 - 31/12/2015
Total amount: 3.389.351,87 €
- 20 Name of the project:** Immune correlates of viral rebound after therapeutic HIV vaccination
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
City of entity: Barcelona,
Nº of researchers: 10
Start-End date: 2013 - 31/01/2014
Total amount: 130.000 €
- 21 Name of the project:** Cutaneous and Mucosal HIV Vaccination (CUT'HIVAC)
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Name principal investigator (PI, Co-PI...): 1
Nº of researchers: 50
Funding entity or bodies:
Comisión Europea **Type of entity:** Entidad Pública de Financiación a nivel europeo
City funding entity: Madrid, Community of Madrid, Spain
Start-End date: 2010 - 2014
Total amount: 11.929.250 €
- 22 Name of the project:** Consequences of Acute HIV infection on the EBV-specific immunity
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Name principal investigator (PI, Co-PI...): J Sanchez; C Brander
Nº of researchers: 4
Funding entity or bodies:
NIH/NIAID
Start-End date: 2010 - 2012
Total amount: 412.000 €
- 23 Name of the project:** Donor HLA restricted T cell responses in HCV-associated OLT
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Nº of researchers: 5
Funding entity or bodies:
Roche Organ Transplantation Research Foundation **Type of entity:** Foundation (ROTRF)
Start-End date: 2010 - 2012
- 24 Name of the project:** Mechanism of late HIV disease progression
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Nº of researchers: 3
Funding entity or bodies:
Type of entity: Foundation



Fundación para la Investigación y la Prevención del Sida en España

Start-End date: 2010 - 2012

Total amount: 163.570 €

- 25 Name of the project:** TOGGLE peptides to assess HIV immunity
Entity where project took place: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
Name principal investigator (PI, Co-PI....): A Llano; C Brander
Nº of researchers: 2
Funding entity or bodies:
 Instituto de Salud Carlos III **Type of entity:** Public Research Body
City funding entity: Majadahonda, Community of Madrid, Spain
Start-End date: 2010 - 2012
Total amount: 128.865 €
- 26 Name of the project:** R01 AI067077-02 - Promiscuous Presentation of HLA Class I Restricted, HIV Derived CTL Epitopes
Entity where project took place: Massachusetts General Hospital **Type of entity:** Healthcare Institutions
City of entity: Boston, United States of America
Funding entity or bodies:
 NIH/NIAID **Type of entity:** State agency
City funding entity: United States of America
Start-End date: 2005 - 2010
- 27 Name of the project:** K56 Impact of HIV diversity on the function of Gag-specific CD4 and CD8 T cells
Entity where project took place: Massachusetts General Hospital **Type of entity:** Healthcare Institutions
City of entity: Boston, United States of America
Funding entity or bodies:
 NIH/NIAID **Type of entity:** State agency
Start-End date: 2007 - 2008
- 28 Name of the project:** N01 AI30024 HLA Typing and Epitope Mapping Relative to HIV Vaccine Design
Entity where project took place: Massachusetts General Hospital **Type of entity:** Healthcare Institutions
City of entity: Boston, Ecuador
Funding entity or bodies:
 NIH-NIAID-DAIDS **Type of entity:** State agency
City funding entity: United States of America
Start-End date: 2003 - 2008
- 29 Name of the project:** U01 AI52748 Solid Organ Transplantation in HIV: Multi-Site Study
Entity where project took place: Massachusetts General Hospital **Type of entity:** Healthcare Institutions
City of entity: Boston,
Funding entity or bodies:
 Instituto de Salud Carlos III **Type of entity:** State agency
City funding entity: United States of America



Start-End date: 2003 - 2008

- 30 Name of the project:** 1 R21 A105542-02
Entity where project took place: Massachusetts General Hospital
City of entity: Boston, United States of America
Funding entity or bodies: Instituto de Salud Carlos III
City funding entity: United States of America
Start-End date: 2005 - 2007
Type of entity: Healthcare Institutions
Type of entity: State agency
- 31 Name of the project:** P30 AI060354 The Impact of HIV Viral Diversity and Cellular Immunity on HIV Pathogenesis
Entity where project took place: Massachusetts General Hospital
City of entity: Boston,
Funding entity or bodies: NIH/NIAID
Start-End date: 2005 - 2007
Type of entity: Healthcare Institutions
Type of entity: State agency
- 32 Name of the project:** 29617001-012R HIV Immunology and Sequence Database
Entity where project took place: Massachusetts General Hospital
City of entity: Boston, United States of America
Funding entity or bodies: Instituto de Salud Carlos III
City funding entity: United States of America
Start-End date: 2001 - 2006
Type of entity: Healthcare Institutions
Type of entity: State agency
- 33 Name of the project:** NO1 AI15442 HLA Typing and Epitope Mapping to Guide HIV Vaccine Design
Entity where project took place: Massachusetts General Hospital
City of entity: Boston, United States of America
Funding entity or bodies: Instituto de Salud Carlos III
City funding entity: United States of America
Start-End date: 2001 - 2006
Type of entity: Healthcare Institutions
Type of entity: State agency
- 34 Name of the project:** P01 DE01438-03 Oral T Cell Responses to EBV, KSHV, and HIV
Entity where project took place: Massachusetts General Hospital
City of entity: Boston, United States of America
Funding entity or bodies: Instituto de Salud Carlos III
City funding entity: United States of America
Start-End date: 2001 - 2006
Type of entity: Healthcare Institutions
Type of entity: State agency

- 35** **Name of the project:** R37 AI28568-12 R37 AI28568-12
Entity where project took place: Massachusetts General Hospital
Type of entity: Healthcare Institutions
City of entity: Boston, United States of America
Funding entity or bodies: NIH/NIAID
Type of entity: State agency
City funding entity: United States of America
Start-End date: 1999 - 2004

R&D non-competitive contracts, agreements or projects with public or private entities

- 1** **Name of the project:** Eclipse Ts2R-FL Inverted Research Microscope
Entity where project took place: FUND. PRIVADA INSITUTO DE RECERCA DE LA SIDA-CAIXA
Degree of contribution: Coordinator of total project, network or consortium
Entity where project took place: FUND. PRIVADA INSITUTO DE RECERCA DE LA SIDA-CAIXA
Funding entity or bodies: Dormeur Foundation, Vaduz
Start date: 01/07/2021
Total amount: 24.706 €
- 2** **Name of the project:** QuantStudio 5 Real Time PCR System
Entity where project took place: FUND. PRIVADA INSTITUT DE INVESTIGACIÓN DEL SIDA-CAIXA
Entity where project took place: FUND. PRIVADA INSTITUT DE INVESTIGACIÓN DEL SIDA-CAIXA
Funding entity or bodies: Dormeur Foundation, Vaduz
Start date: 01/01/2019
Total amount: 25.000 €
- 3** **Name of the project:** Identification of epigenetically regulated plasma factors associated with neuro-degeneration
Funding entity or bodies: GRIFOLS, S.A.
Start date: 01/07/2018
Duration: 5 years
Total amount: 600.000 €
- 4** **Name of the project:** HIVACAT
Degree of contribution: Scientific coordinator
Name principal investigator (PI, Co-PI....): B Clotet; Jm Gatell; C Brander
Start date: 2008
Total amount: 12.000.000 €
- 5** **Name of the project:** HLA Typing and Epitope Mapping Relative to HIV Vaccine Design
Degree of contribution: Coordinator of total project, network or consortium
Name principal investigator (PI, Co-PI....): C Brander
Nº of researchers: 25
Start date: 2003
Duration: 4 years
Total amount: 14.000.000 €

Results

Industrial and intellectual property

- 1** **Title registered industrial property:** Dosage Regimens for Vaccination
Inventors/authors/obtainers: Beatriz Mothe; Christian Brander
Entity holder of rights: AELIX Therapeutics
N° of application: E2019ADI07210024
Country of inscription: United States of America
Date of register: 14/11/2019

- 2** **Title registered industrial property:** Method for inducing a DTH reaction using defined CTL epitopes
Inventors/authors/obtainers: Christian Brander; Marta Ruiz Riol
Entity holder of rights: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
N° of application: US 61/533476
Date of register: 12/09/2012
Companies: Laboratorios Dr. Esteve, S.A.

- 3** **Title registered industrial property:** Método para seguir las respuestas de células T específicas al VIH
Inventors/authors/obtainers: Christian Brander; Marta Ruiz-Riol; Javier Ibarrondo
Entity holder of rights: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
N° of application: ESTA-1206-EP P8270EP00
Country of inscription: Spain
Date of register: 18/04/2012
Companies: Laboratorios Dr. Esteve, S.A.

- 4** **Title registered industrial property:** HIV T-cell overlapping peptide (OLP) immunogens
Inventors/authors/obtainers: Christian Brander; Beatriz Mothe; Anuska Llano
Entity holder of rights: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
N° of application: EP 12382031.8
Country of inscription: Spain
Date of register: 27/01/2012
Companies: Laboratorios Dr. Esteve, S.A.

- 5** **Title registered industrial property:** Highly immunogenic HIV Gag p24 sequences
Inventors/authors/obtainers: Christian Brander; Beatriz Mothe; James Mullins
Entity holder of rights: FUND. PRIVADA INSTITUTO DE INVESTIGACION DE LA SIDA-CAIXA
N° of application: EP2011/069870 // US 61/412060
Country of inscription: Spain
Date of register: 10/11/2010
Companies: Laboratorios Dr. Esteve, S.A.



Scientific and technological activities

Scientific production

H index: 89

Date of application: 04/01/2024

Fuente de Índice H: GOOGLE SCHOLAR

Publications, scientific and technical documents

- 1** Carla Anjos-Souza; Juan Blanco-Heredia; Juan Trincado; Maria Gonzalez-Cao; Samuel Gonçalves-Ribeiro; Sara Ruiz Gil; Dmytro Pravdyvets; Clare Puttick; Samandhy Cedeño; Maurizio Callari; Antonio Marra; Andrea Gazzo; Britta Weigelt; Fresia Pareja; Theodore Vougiouklakis; Achim Jungbluth; Nicholas McGranahan; Rafael Rosell; Christian Brander; Francesc Tresserra; Jorge Reis-Filho; Daniel Tiezzi; Nuria de la Iglesia; Holger Heyn; Leticia De Mattos-Arruda. Converging and evolving immuno-genomic routes towards immune escape in breast cancer. Nature Communications. in press, Nature, 2024.

Type of production: Scientific paper **Format:** Journal

Position of signature: 19 **Corresponding author:** No

Total no. authors: 25
- 2** Clara Duran-Castells; Anna Prats; Bruna Oriol-Tordera; Anuska Llano; Cristina Galvez; Javier Martinez-Picado; Ester Ballana; Edurne Garcia-Vidal; Bonaventura Clotet; Jose Muñoz-Moreno; Tomas Hanke; Jose Molto; Beatriz Mothe; Christian Brander; Marta Ruiz-Riol. Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination. EBioMedicine. 95 - 104732, The Lancet, 2023.

Type of production: Scientific paper **Format:** Journal

Position of signature: 14 **Corresponding author:** No

Total no. authors: 15
- 3** Mie Kobayashi-Ishihara; Katarina Frazão Smutná; Florencia Alonso; Jordi Argilagué; Anna Esteve-Codina; Kerstin Geiger; Meritxell Genescà; Judith Grau-Expósito; Clara Duran-Castells C; Selina Rogenmoser; Rene Böttcher; Jennifer Jungfleisch; Baldomero Oliva; Javier Martinez; Manqing Li; Michael David; Makoto Yamagishi; Marta Ruiz-Riol; Christian Brander; Yasuko Tsunetsugu-Yokota; Maria Jose Buzon; Juana Diez; Andraes Meyerhans. Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells. Commun Biol. 6 - 1, pp. 487. Nature, 2023.

Type of production: Scientific paper **Format:** Journal

Position of signature: 19 **Corresponding author:** No

Total no. authors: 23
- 4** Clara Duran-Castells; Anuska Llano; Ai Kawana-Tachikawa; Anna Prats; Igancio Martinez-Zalacain; Mie Kobayashi-Ishihara; Bruna Oriol-Tordera; Ruth Peña; Cristina Gálvez; Sandra Silva-Arrieta; Clotet Clotet; Eva Riveira-Muñoz; Ester Ballana; Julia Garcia Prado; Javier Martinez-Picado; Beatriz Mothe; Dennis Hartigan-O'Connor; Tony Wyss-Coray; Andreas Meyerhans; Magnus Gisslén; Richard Price; Carles Soriano-Mas; Jose Muñoz-Moreno; Christian Brander; Marta Ruiz-Riol. Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction. J Virol.97 - 2, pp. 2023 Feb 28;97(2):e0165522. ASM, 2023.

Type of production: Scientific paper **Format:** Journal

Position of signature: 24 **Corresponding author:** No

Total no. authors: 25



- 5** Aleix Elizalde-Torrent; Alessandra Borgognon; Maria Casadellà; Luis Romero-Martin; Tuixent Escribà; Mariona Parera; Yaiza Rosales-Salgado; Jorge Díaz-Pedroza; Francesc Català-Moll; Marc Noguera-Julian; Christian Brander; Roger Paredes; Alex Olvera. Vaccination with an HIV T-cell immunogen induces alterations in the mouse gut microbiota. *Vaccines*. 11 - 11, pp. 1663. MDPI, 2023.
Type of production: Scientific paper **Format:** Journal
Position of signature: 11
Total no. authors: 13 **Corresponding author:** No
- 6** Gemma Lladós; Marta Massanella; Roser Coll-Fernández; Raul Rodríguez; Electra Hernández; Giuseppe Lucente; Cristina Lopez; Cora Loste; José Ramón Santos; Sergio España-Cueto; Maria Nevot; Sandra Silva-Arrieta; Christian Brander; Lourdes Mateu. Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross-sectional study. *Clin Microbiol Infect*. S1198-743X - 23, Elsevier, 2023.
Type of production: Scientific paper **Format:** Journal
Position of signature: 13
Total no. authors: 25 **Corresponding author:** No
- 7** Lucia Bailón; Anuska Llano; Samandhy Cedeño; Tuixent Escribà; Miriam Rosás-Umbert; Mariona Parera; Maria Casadellà; Miriam Lopez; Francisco Pérez; Bruna Oriol-Tordera; Marta Ruiz-Riol; Josep Coll; Felix Perez; Ángel Rivero; Anne R Leselbaum; Ian McGowan; Devi Sengupta; Edmund G Wee; Tomáš Hanke; Roger Paredes; Yovaninna Alarcón-Soto; Bonaventura Clotet; Marc Noguera-Julian; Christian Brander; Jose Molto; Beatriz Mothe; {AELIX002 Study Group}. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. *Nature Medicine*. 28 - 12, pp. 2611—2621 - 2611—2621. 12/2022. Available on-line at: <<https://doi.org/10.1038/s41591-022-02060-2>>.
Type of production: Scientific paper **Format:** Journal
Position of signature: 24
Total no. authors: 27 **Corresponding author:** Yes
- 8** Alessandra Borgognone; Aleix Elizalde-Torrent; Maria Casadellà; Luis Romero; Tuixent Escribà; Mariona Parera; Francesc Català-Moll; Marc Noguera-Julian; Christian Brander; Alex Olvera; Roger Paredes. Vaccination with an HIV T-cell immunogen induces alterations in the mouse gut microbiota. *NPJ biofilms and microbiomes*. 8 - 1, pp. 104 - 104. 12/2022. Available on-line at: <<https://europepmc.org/articles/PMC9801356>>.
Type of production: Scientific paper **Format:** Journal
Position of signature: 9
Total no. authors: 11 **Corresponding author:** No
- 9** Miriam Rosás-Umbert; Jesper D Gunst; Marie H Pahu; Rikke Olesen; Mariane Schleimann; Paul W Denton; Victor Ramos; Adam Ward; Natalie N Kinloch; Dennis C Copertino; Tuixent Escribà; Anuska Llano; Zabrina L Brumme; R Brad Jones; Beatriz Mothe; Christian Brander; Julie Fox; Michel C Nussenzweig; Sarah Fidler; Marina Caskey; Martin Tolstrup; Ole S Søggaard. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8⁺ T cell immunity. *Nature Communications*. 13 - 1, pp. 6473 - 6473. 10/2022. Available on-line at: <<https://europepmc.org/articles/PMC9617872>>. ISSN 2041-1723
Type of production: Scientific paper **Format:** Journal
Position of signature: 16
Total no. authors: 22 **Corresponding author:** No
- 10** Luis Romero-Martin; Clara Duran-Castells; Mireia Olivella; Miriam Rosás-Umbert; Marta Ruiz-Riol; Jorge Sanchez; Dennis Hartigan-O Connor; Beatriz Mothe; Alex Olvera; Christian Brander. Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections. *Frontiers In Immunology*. 13 - 1027855, Frontiers, 2022.
Type of production: Scientific paper **Format:** Journal
Position of signature: 10
Total no. authors: 10 **Corresponding author:** Yes



- 11** Bruna Oriol-Tordera; Anna Esteve-Codina; Maria Berdasco; Miriam Rosás-Umbert; Elena Gonçalves; Clara Duran-Castells; Francesc Català-Moll; Anuska Llano; Samandhy Cedeño; Maria Puertas; Martin Tolstrup; Ole Søggaard; Bonaventura Clotet; Javier Martínez-Picado; Tomas Hanke; Behazine Combadiere; Roger Paredes; Dennis Hartigan-O'Connor; Manuel Esteller; Michael Meulbroek; Maria Luz Calle; Alex Sanchez-Pla; Jose Molto; Beatriz Mothe; Christian Brander; Marta Ruiz-Riol. Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. *EBioMedicine*. 78 - 103956, 2022.
- Type of production:** Scientific paper **Format:** Journal
Position of signature: 25
Total no. authors: 26 **Corresponding author:** No
- 12** Aguado-Garcia Diana; Alex Olvera; Brander Christian; Victor Sanchez-Marino; Yuste Eloisa. Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope. *Basel*. 10 - 4, pp. 4. MDPI, 2022.
- Type of production:** Scientific paper **Format:** Journal
Position of signature: 3
Total no. authors: 5 **Corresponding author:** No
- 13** Erola Ainsua-Enrich; Nuria Pedreño-Lopez; Carmen Bracke; Carlos Ávila-Nieto; Maria Luisa Rodríguez de la Concepción; Edwards Pradenas; Benjamin Trinité; Silvia Marfil; Cristina Miranda; Sandra González; Ruth Toledo; Marta Font; Susana Benet; Tuixent Escibà; Esther Jimenez-Moyano; Ruth Peña; Samandhy Cedeño; Julia Prado; Beatriz Mothe; Christian Brander; Nuria Izquierdo-Useros; Julia Vergara-Alert; Joaquim Segalés; Marta Massanella; Rosa María Benitez; Alba Romero; Daniel Molina-Morant; Julià Blanco; Bonaventura Clotet; Lourdes Mateu; María Luisa Pedro-Botet; Jorge Carrillo. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals. *iScience*. 25 - 11, pp. 105455. *Science*, 2022.
- Type of production:** Scientific paper **Format:** Journal
Position of signature: 20
Total no. authors: 32 **Corresponding author:** No
- 14** Susana Benet; Oscar Blanch-Lombarte; Erola Ainsua-Enrich; Núria Pedreño-Lopez; Jordana Muñoz-Basagoiti; Dàlia Raïch-Regué; Daniel Perez-Zsolt; Ruth Peña; Christian Brander; Beatriz Mothe. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution. *J. Inf. Dis.* 226 - 11, pp. 913 - 1923. Oxford Academic, 2022.
- Type of production:** Scientific paper **Format:** Journal
Position of signature: 22
Total no. authors: 30 **Corresponding author:** No
- 15** Athina Kilpeläinen; Esther Jimenez-Moyano; Oscar Blanch-Lombarte; Dan Ouchi; Ruth Peña; Bibiana Quirant-Sanchez; Raul Perez-Caballero; Anna Chamorro; Ignacio Blanco; Eva Martínez-Caceres; Roger Paredes; Lourdes Mateu; Jorge Carrillo; Julian Blanco; Christian Brander; Marta Massanella; Bonaventura Clotet; Julia Prado. Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. *Front Immunol*. 13 - 815, *Frontiers*, 2022.
- Type of production:** Scientific paper **Format:** Journal
Position of signature: 15
Total no. authors: 18 **Corresponding author:** No
- 16** Dennis Hartigan-O'Connor; Luis Romero-Martin; Ferran Tarrés-Freixas; Nuria Pedreño-López; Maria Rodríguez de la Concepción; Francesc Cunyat; Jorge Carrillo; Beatriz Mothe; Julian Blanco; Marta Ruiz-Riol; Christian Brander; Alex Olvera. T-Follicular-Like CD8+ T Cell Responses in Chronic HIV Infection Are Associated With Virus Control and Antibody Isotype Switching to IgG. *Front Immunol*. 13 - 928039, *Frontiers*, 2022.
- Type of production:** Scientific paper **Format:** Journal
Position of signature: 11
Total no. authors: 12 **Corresponding author:** No



- 17** L Bailon; et.al.. A placebo-controlled ATI trial of HTI vaccines in early treated HIV infection. Topics in Antiviral Medicine. pp. 48 - 49. 2021.
Type of production: Scientific paper
Position of signature: 12
Total no. authors: 14
- 18** Vinicius Vieira; Emily Adland; David Malone; Maureen Martin; Andreas Groll; Ansim Azari; Maria Garcia-Guerrero; Mari Carmen Puertas; Christian Brander; Philip Goulder. An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathog .17 - 11, 2021.
DOI: 10.1371/journal.ppat.1010090.
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 22
Corresponding author: No
- 19** Gemma Méndez-Lagares; et. al.. Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing function. The Journal of Clinical Investigation. 131 - 15, 2021.
DOI: 10.1172/JCI148542
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 14
- 20** Alex Olvera; et. al.; Christian Brander. Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?. Front Immunol.11:573928, 2021.
DOI: doi: 10.3389/fimmu.2020.573928
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 7
Corresponding author: Yes
- 21** A Kilpeläinen; et.al.. High-resolution mapping of T-cell immunity to the entire sarscov-2 proteome. Topics in Antiviral Medicine. pp. 89 - 90. 2021.
Type of production: Scientific paper
Position of signature: 13
Total no. authors: 15
- 22** E Gonçalves; et.al.. Host Transcriptome and Microbiota Signatures Prior to Immunization Profile Vaccine Humoral Responsiveness. Front Immunol .12, pp. 657162. 2021.
DOI: 10.3389/fimmu.2021.657162.
Type of production: Scientific paper
Position of signature: 5
Total no. authors: 7
- 23** Hongbing Yang; et. al.. Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8 + T cell antiviral responses. Cell Rep.35 - 6, pp. 109103. 2021.
DOI: 10.1016/j.celrep.2021.109103.
Type of production: Scientific paper
Position of signature: 15
Total no. authors: 17



- 24** M Vignoles; et. al.. Persistent HIV-1 transcription in CD4+ T cells from ART-suppressed individuals can originate from biologically competent proviruses. *J Virus Erad* .2021.
DOI: 10.1016/j.jve.2021.100053
Type of production: Scientific paper
Position of signature: 4
Total no. authors: 9
- 25** J Moltó; et.al.. Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. *J Antimicrob Chemother* .76 - 4, pp. 1032 - 1040. 2021.
DOI: 10.1093/jac/dkaa523.
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 13
- 26** C Beltran-Pavez; et.al.. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle (VLP) Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. *J Virol* .pp. 01343-21. 2021.
DOI: 10.1128/JVI.01343-21.
Type of production: Scientific paper
Position of signature: 8
Total no. authors: 12
- 27** Jose A Muñoz-Moreno; et. al. Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy. *AIDS*. 2021.
DOI: 10.1097/QAD.0000000000003121
Type of production: Scientific paper
Position of signature: 11
Total no. authors: 15
- 28** Vinicius A Vieira; et. al.. Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors. *AIDS*. 2021.
DOI: 0.1097/QAD.0000000000003078
Type of production: Scientific paper
Position of signature: 13
Total no. authors: 17
- 29** B Oriol-Tordera; A Olvera; C Duran-Castells; Llano; B Mothe; M Massanella; J Dalmau; C Ganoza; J Sanchez; ML Calle; B Clotet; J Martinez-Picado; E Negredo; J Blanco; D Hartigan-O'Connor; C Brander; M Ruiz-Riol. TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses. *J Immunol*.205(12);, pp. 3348 - 3357. 11/11/2020.
DOI: doi: 10.4049/jimmunol.2000933
Type of production: Scientific paper
Position of signature: 16
Total no. authors: 17
Corresponding author: Yes
- 30** J Sanchez; E Gonçalves; A Llano; P Gonzáles; M Fernández-Maldonado; A Vogt; A Soria; S Perez; S Cedeño; MA Fernández; J Nourikyan; S de Bernard; C Ganoza; E Pedruzzi; O Bonduelle; B Mothe; CE Gòmez; M Esteban; F Garcia; JR Lama; C Brander; C Combadiere. Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study. *Front Immunol*.11:586124, 10/11/2020.
DOI: 10.3389/fimmu.2020.586124
Type of production: Scientific paper
Position of signature: 21

**Total no. authors:** 22**Corresponding author:** No

- 31** B Oriol-Tordera; B Mothe; M Berdasco; A Llano; C Gálvez; J Martínez-Picado; J Carrillo; J Blanco; C Duran-Castells; C Ganoza; J Sanchez; B Clotet; ML Calle; A Sánchez-Pla; M Esteller; C Brander; M Ruiz-Riol. Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. *PLoS Pathog.*16(8), 06/08/2020.

DOI: 10.1371/journal.ppat.1008678**Type of production:** Scientific paper**Position of signature:** 16**Total no. authors:** 17**Corresponding author:** No

- 32** A Olvera; M Noguera-Julian; A Kilpelainen; L Romero-Martín; JG Prado; C Brander. SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design for COVID19 Immune Studies and Vaccine Development. *Vaccines.* 8(3):444, 06/08/2020.

DOI: doi: 10.3390/vaccines8030444**Type of production:** Scientific paper**Position of signature:** 6**Total no. authors:** 6**Corresponding author:** Yes

- 33** S Moron-Lopez; V Urrea; J Dalmau; M Lopez; MC Puertas; D Ouchi; A Gómez; C Passaes; B Mothe; C Brander; A Saez-Cirion; B Clotet; M Esteller; M Berdasco; J Martínez-Picado. The genome-wide methylation profile of CD4+ T cells from HIV-infected individuals identifies distinct patterns associated with disease progression. *Clin Infect Dis.*26/07/2020.

DOI: 10.1093/cid/ciaa1047**Type of production:** Scientific paper**Position of signature:** 10**Total no. authors:** 15**Corresponding author:** No

- 34** T Sekine; A Perez-Potti; S Nguyen; JB Gorin; WH Wu; E Gostick; S Llewellyn-Lacey; Q Hammer; S Falck-Jones; S Vangeti; M Yu; A Smed-Sørensen; A Gaballa; M Uhlin; JK Sandberg; C Brander; P Nowak; PA Goepfert; DA Price; MR Betts; M Buggert. TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells. *Sci Immunol.*5(49), 03/07/2020.

DOI: 10.1126/sciimmunol.aba7918**Type of production:** Scientific paper**Position of signature:** 16**Total no. authors:** 21**Corresponding author:** No

- 35** S Silva-Arrieta; PJR Goulder; C Brander. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. *PLoS Pathog.* 16(6):e1008607, 04/06/2020.

DOI: 10.1371/journal.ppat.1008607**Type of production:** Scientific paper**Position of signature:** 3**Total no. authors:** 3**Corresponding author:** Yes

- 36** B Mothe; M Rosás-Umbert; P Coll; C Manzardo; MC Puertas; S Morón-López; A Llano; C Miranda; S Cedeño; M López; Y Alarcón-Soto; GG Melis; K Langohr; AM Barriocanal; J Toro; I Ruiz; C Rovira; A Carrillo; M Meulbroek; A Crook; EG Wee; JM Miró; B Clotet; M Valle; J Martínez-Picado; T Hanke; C Brander; J Moltó; BCN02 Study Investigators. HIVconsV Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). *Front Immunol.*11:823, 06/05/2020.

DOI: 10.3389/fimmu.2020.00823**Type of production:** Scientific paper**Position of signature:** 27**Total no. authors:** 28**Corresponding author:** No



- 37** VM Andrade; C Mavian; D Babic; T Cordeiro; M Sharkey; L Barrios; C Brander; J Martinez-Picado; J Dalmau; A Llano; JZ Li; J Jacobson; CL Lavine; MS Seaman; M Salemi; M Stevenson. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. *Proc Natl Acad Sci U S A.* 117(18), pp. 9981 - 9990. 05/05/2020.
DOI: 10.1073/pnas.1917034117
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 16 **Corresponding author:** No
- 38** M Rosás-Umbert; M Ruiz-Riol; MA Fernández; M Marszalek; P Coll; C Manzardo; S Cedeño; JM Miró; B Clotet; T Hanke; J Moltó; B Mothe; C Brander. In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Rosás-Umbert M, Ruiz-Riol M, Fernández MA, Marszalek M, Coll P, Manzardo C, Cedeño S, Miró JM, Clotet B, Hanke T, Moltó J, Mothe B, Brander C; BCN02 study group. *Front Immunol.*11:418, 20/03/2020.
DOI: doi: 10.3389/fimmu.2020.00418
Type of production: Scientific paper
Position of signature: 13
Total no. authors: 13 **Corresponding author:** Yes
- 39** A Gallinaro; et.al.. Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. *Mol Ther Methods Clin Dev.*17, pp. 418 - 428. 2020.
DOI: 10.1016/j.omtm.2020.01.013.
Type of production: Scientific paper
Position of signature: 10
Total no. authors: 12
- 40** A Bayón-Gil; et.al.. HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design. *J Antimicrob Chemother.*75 - 8, pp. 2258 - 2263. 2020.
DOI: 10.1093/jac/dkaa139.
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 9
- 41** L Bailon; C Brander. Novel Approaches Towards a Functional Cure of HIV/AIDS. *Drugs.* 80 - 9, pp. 859 - 868. 2020.
DOI: 10.1007/s40265-020-01322-y.
Type of production: Scientific paper
Position of signature: 4
Total no. authors: 4
- 42** Nicola Borthwick; Sandra Silva-Arrieta S; Anuska Llano; M Takiguchi; Christian Brander; Nicola Borthwick; Tom Hanke. Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines. *Vaccines.* 8 - 1, 2020.
DOI: 10.3390/vaccines8010028
Type of production: Scientific paper **Format:** Journal
Corresponding author: No
- 43** N Saubi; et.al.. Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice. *Vaccines (Basel).*8 - 4, pp. 678. 2020.
DOI: 10.3390/vaccines8040678.
Type of production: Scientific paper

Position of signature: 7

Total no. authors: 8

- 44** B Mothe; C Brander. Small steps forward for HIV vaccine development. *Nat Med.* 26 - 4, pp. 466 - 467. 2020.
DOI: 10.1038/s41591-020-0837-0
Type of production: Scientific paper
Position of signature: 2
Total no. authors: 2
- 45** Yehia S Mohamed; et.al.. Specificity of CD8 + T-Cell Responses Following Vaccination with Conserved Regions of HIV-1 in Nairobi, Kenya. *Vaccines (Basel).* 8 - 2, pp. 260. 2020.
DOI: 10.3390/vaccines8020260.
Type of production: Scientific paper
Position of signature: 15
Total no. authors: 17
- 46** W de Jong; J Aerts; S Allard; C Brander; J Buyze; E Florence; E van Gorp; G Vanham; L Leal; B Mothe; K Thielemans; M Plana; F Garcia; R Gruters. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. *Trials.* 20 - 1, pp. 721. 13/12/2019.
DOI: 10.1186/s13063-019-3409-1
Type of production: Scientific paper
- 47** W Jong; L Leal; J Buyze; P Pannus; A Guardo; M Salgado; B Mothe; J Molto; S Moron-Lopez; C Gálvez; E Florence; G Vanham; EV Gorp; C Brander; S Allard; K Thielemans; J Martinez-Picado; M Plana; F García; RA Gruters. Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. *Vaccines.* 7 - 4, 06/12/2019.
DOI: 10.3390/vaccines7040209
Type of production: Scientific paper
- 48** E Couto; V Diaz-Brito; B Mothe; AC Guardo; I Fernandez; A Ugarte; F Etcheverry; CE Gómez; M Esteban; J Pich; JA Arnaiz; JC López Bernaldo de Quirós; C Brander; M Plana; F García. Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B. *Vaccines.* 7 - 4, 07/11/2019.
DOI: 10.3390/vaccines7040178
Type of production: Scientific paper
- 49** M Ruiz-Riol; C Brander. Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity. *Immunotherapy.* 11(11), pp. 931 - 935. 11/08/2019.
DOI: 10.2217/imt-2019-0092
Type of production: Scientific paper
Position of signature: 2
Total no. authors: 2 **Corresponding author:** Yes
- 50** A Kilpeläinen; N Saubi; N Guitart; A Olvera; T Hanke; C Brander; J Joseph. Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice. *Vaccines.* 7 - 3, 02/08/2019.
DOI: 10.3390/vaccines7030078
Type of production: Scientific paper
Position of signature: 6
Total no. authors: 7



- 51** M Ruiz-Riol; C Brander. Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity. *Immunotherapy*. 11 - 11, pp. 931 - 935. 01/08/2019.
DOI: 10.2217/imt-2019-0092
Type of production: Scientific paper
- 52** B Mothe; C Manzardo; A Sanchez-Bernabeu; P Coll; S Morón-López; MC Puertas; M Rosas-Umbert; P Cobarsi; R Escrig; N Perez-Alvarez; I Ruiz; C Rovira; M Meulbroek; A Crook; N Borthwick; EG Wee; H Yang; JM Miró; L Dorrell; B Clotet; J Martinez-Picado; C Brander. Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). *EClinicalMedicine*. 11, pp. 65 - 80. 05/06/2019.
DOI: 10.1016/j.eclinm.2019.05.009
Type of production: Scientific paper
Position of signature: 22
Total no. authors: 22
- 53** C Tumiotto; BM Alves; P Recordon-Pinson; M Jourdain; P Bellecave; GL Guidicelli; J Vinsentin; F Bonnet; M Hessamfar; D Neau; J Sanchez; C Brander; M Sajadi; L Eyzaguirre; EA Soares; JP Routy; MA Soares; H Fleury. Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. *PLoS One*. 14 - 2, 27/02/2019.
DOI: 10.1371/journal.pone.0212347
Type of production: Scientific paper
- 54** M Rosás-Umbert; A Llano; R Bellido; A Olvera; M Ruiz-Riol; M Rocafort; MA Fernández; P Cobarsi; M Crespo; L Dorrell; J Del Romero; J Alcami; R Paredes; C Brander; B Mothe. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers. *J Virol*. 93 - 4, 05/02/2019.
DOI: 10.1128/JVI.01436-18
Type of production: Scientific paper
Position of signature: 14
Total no. authors: 15
Corresponding author: No
- 55** VA Vieira; P Zuidewind; M Muenchhoff; J Roider; J Millar; M Clapson; A Van Zyl; D Shingadia; E Adland; R Athavale; N Grayson; MA Ansari; C Brander; CF Guash; L Naver; T Puthanakit; WN Songtaweasin; J Ananworanich; D Peluso; B Thomé; J Pinto; P Jooste; G Tudor-Williams; MF Cotton; P Goulder. Strong sex bias in elite control of paediatric HIV infection. *AIDS*. 33 - 1, pp. 67 - 75. 27/01/2019.
DOI: 10.1097/QAD.0000000000002043
Type of production: Scientific paper
- 56** N Colomar-Carando; A Meseguer; I Company-Garrido; S Jutz; V Herrera-Fernández; A Olvera; K Kiefer; C Brander; P Steinberger; R Vicente. Zip6 Transporter Is an Essential Component of the Lymphocyte Activation Machinery. *J Immunol*. 202 - 2, pp. 441-450. 15/01/2019.
DOI: 10.4049/jimmunol.1800689
Type of production: Scientific paper
- 57** Y Guillén; M Noguera-Julian; J Rivera; M Casadellà; AS Zevin; M Rocafort; M Parera; C Rodríguez; M Arumí; J Carrillo; B Mothe; C Estany; J Coll; I Bravo; C Herrero; J Saz; G Sirera; A Torrella; J Navarro; M Crespo; E Negro; C Brander; J Blanco; ML Calle; NR Klatt; B Clotet; R Paredes. Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. *Mucosal Immunol*. 12 - 1, pp. 232 - 246. 01/2019.
DOI: 10.1038/s41385-018-0083-7
Type of production: Scientific paper



- 65** M Rosás-Umbert; B Mothe; M Noguera-Julian; R Bellido; MC Puertas; J Carrillo; C Rodriguez; N Perez-Alvarez; P Cobarsí; CE Gomez; M Esteban; JL Jimenez; F Garcia; J Blanco; J Martínez-Picado; R Paredes; C Brander. Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PlosOne. 12 - 9, pp. e0184929. 27/09/2017.
Type of production: Scientific paper
Position of signature: 17
Total no. authors: 17
Corresponding author: Yes
- 66** C Tumiotto; L Riviere; P Bellecave; P Recordon-Pinson; A Vilain-Parce; GL Guidicelli; H Fleury; (WainbergRoutyDuponNeauSanchezBrander) Provir/Latitude 45 collaborating group. Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA. PlosOne. 12 - 9, pp. e0185211. 21/09/2017.
Type of production: Scientific paper
- 67** M Ruiz-Riol; D Berdnik; A Llano; B Mothe; C Galvez; S Pérez-Álvarez; B Oriol-Tordera; A Olvera; S Silva-Arrieta; M Meulbroek; F Pujol; J Coll; J Martinez-Picado; C Ganoza; J Sanchez; G Gomez; T Wyss-Coray; C Brander. Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control. J. Virol. 91 - 16, pp. e00441. 27/07/2017.
Type of production: Scientific paper
Format: Journal
Position of signature: 18
Total no. authors: 18
Corresponding author: Yes
- 68** O Oriol-Tordera; A Llano; C Ganoza; S Cate; W Hildebrand; J Sanchez; ML Calle; C Brander; A Olvera. Impact of HLA-DRB1 allele polymorphisms on control of HIV infection in a Peruvian MSM cohort. HLA. 90 - 4, pp. 234 - 237. 05/07/2017.
Type of production: Scientific paper
Format: Journal
Position of signature: 8
Total no. authors: 9
- 69** N Borthwick; Z Lin; T Akahoshi; A Llano; S Silva-Arrieta; T Ahmed; L Dorrell; C Brander; H Murakoshi; M Takiguchi; T Hanke. Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines. Plos One. 12(4):e0176418, 07/06/2017.
Type of production: Scientific paper
Format: Journal
Corresponding author: No
- 70** A Carreras-Sureda; F Rubio-Moscardo; A Olvera; J Argilaguuet; K Kiefer; B Mothe; A Meyerhans; C Brander; R Vicente. Lymphocyte activation dynamics is shaped by hereditary components at chromosome region 17q12-q21. Plos One. In press, 11/11/2016.
Type of production: Scientific paper
Format: Journal
Position of signature: 8
Total no. authors: 9
- 71** F García; AC Guardo; PT Joe; L Miralles; ME Bargalló; B Mothe; A Krasniqi; C Heirman; F Garcia; K Thielemans; C Brander; JL Aerts; M Plana; iHIVARNA Consortium. Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix). AIDS. Epub ahead of print, 24/09/2016.
Type of production: Scientific paper
- 72** M Sironi; M Biasin; C Pontremoli; R Cagliani; I Saulle; D Trabattoni; F Vichi; S Lo Caputo; F Mazzotta; W Aguilar-Jimenez; MT Rugeles; S Cedeno; J Sanchez; C Brander; M Clerici. Variants in the CYP7B1 gene region do not affect natural resistance to HIV-1 infection. Variants in Retrovirology. 12:80. doi:10.1186, 24/09/2016.
Type of production: Scientific paper
Format: Journal



- 73** M Biasin; M Sironi; I Saulle; C Pontremoli; M Garziano; R Cagliani; D Trabattoni; S Lo Caputo; F Vichi; F Mazzotta; D Forni; S Riva; W Aguilar-Jimenez; S Cedeño; J Sanchez; C Brander; W Zapata; MT Rugeles; M Clerici. A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. *Microbes Infect.* S1286-4579(16) - 30132-0, 18/09/2016.
Type of production: Scientific paper **Format:** Journal
- 74** N Rallón; B Mothe; JM Lopez de Quiros; M Plana; JM Ligos; M Montoya; MA Muñoz-Fernández; M Esteban; F García; C Brander; JM Benito; RISVAC03 Study Group. Balance between activation and regulation of HIV-specific CD8+ T-cell response after modified vaccinia Ankara B therapeutic vaccination. *AIDS.* 30(4), pp. 553 - 562. 20/02/2016.
Type of production: Scientific paper **Format:** Journal
Position of signature: 10
Total no. authors: 12
- 75** M Noguera-Julian; M Rocafort; Y Guillén; J Rivera; M Casadellà; P Nowak; F Hildebrand; G Zeller; M Parera; R Bellido; C Rodríguez; J Carrillo; B Mothe; J Coll; J Bravo; C Estany; C Herrero; J Saz; G Sirera; A Torrela; J Navarro; M Crespo; C Brander; E Negro; J Blanco; F Guarner; ML Calle; P Bork; A Sönnernborg; B Clotet; R Paredes. Gut Microbiota Linked to Sexual Preference and HIV Infection. *EBioMedicine.* 28(5), pp. 135 - 146. 28/01/2016.
Type of production: Scientific paper **Format:** Journal
Position of signature: 23
Total no. authors: 31 **Corresponding author:** No
- 76** N Ternette; H Yang; T Partridge; A Llano; S Cedeño; R Fischer; PD Charles; NL Dudek; B Mothe; M Crespo; WM Fischer; BT Korber; M Nielsen; P Borrow; AW Purcell; C Brander; L Dorrell; BM Kessler; T Hanke. Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. *Eur J Immunol.* . 46(1), pp. 60 - 69. 26/01/2016.
Type of production: Scientific paper **Format:** Journal
Position of signature: 16
Total no. authors: 19
- 77** J Blanco-Heredia; A Lecanda; H Valenzuela-Ponce; C Brander; S Ávila-Ríos; G Reyes-Terán. Identification of Immunogenic Cytotoxic T Lymphocyte Epitopes Containing Drug Resistance Mutations in Antiretroviral Treatment-Naïve HIV-Infected Individuals. *Plos One.* 11(1):e0147571, 25/01/2016.
Type of production: Scientific paper **Format:** Journal
Position of signature: 4
Total no. authors: 6
- 78** A Shahid; A Olvera; G Anmole; XT Kuang; LA Cotton; M Plana; C Brander; MA Brockman; ZL Brumme. Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function. *J Virol.* 89(22), pp. 11557-11571. 11/11/2015.
Type of production: Scientific paper **Format:** Journal
- 79** 1; CE Gómez; B Perdiguero; J García-Arriaza; V Cepeda; CO Sánchez-Sorzano; B Mothe; JL Jiménez; MA Muñoz-Fernández; JM Gatell; JC López Bernaldo de Quirós; C Brander; F García; M Esteban. A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. *Plos One.* 10(11):e0141456, 06/11/2015.
Type of production: Scientific paper **Format:** Journal
- 80** J Nowakowska; C Stuehler; A Egli; M Battegay; G Rauser; GR Bantug; C Brander; C Hess; N Khanna. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells. *Cytotherapy.* 17(9), pp. 1280 - 1291. 01/09/2015.
Type of production: Scientific paper **Format:** Journal

**Position of signature:** 7**Total no. authors:** 9**Corresponding author:** No

- 81** AC Guardo; M Ruiz-Riol; E Fernández; MJ Maleno; ME Bargalló; A León; N Climent; F García; JM Gatell; C Brander; M Plana. Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture. *AIDS*. 29(11), pp. 1309 - 1318. 17/07/2015.
Type of production: Scientific paper **Format:** Journal
- 82** GJ Xu; T Kula; Q Xu; MZ Li; SD Vernon; T Ndung'u; K Ruxrungtham; J Sanchez; C Brander; RT Chung; KC O'Connor; B Walker; HB Larman; SJ Elledge. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. *Science*. 348(6239):aaa0698, 05/06/2015.
Type of production: Scientific paper **Format:** Journal
Position of signature: 9
Total no. authors: 14 **Corresponding author:** No
- 83** CT Berger; A Llano; JM Carlson; ZL Brumme; MA Brockman; S Cedeño; PR Harrigan; DE Kaufmann; D Heckerman; A Meyerhans; C Brander. Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1. *J Virol*. 89(7), pp. 4015 - 4019. 01/04/2015.
Type of production: Scientific paper
- 84** M Ruiz-Riol; A Llano; J Ibarrodo; J Zamarreño; K Yusim; V Bach; B Mothe; S Pérez-Álvarez; MA Fernandez; G Requena; M Meulbroek; F Pujol; A León; P Cobarsi; BT Korber; B Clotet; C Ganoza; J Sanchez; J Coll; C Brander. Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. *J Infect Dis*. 211(6), pp. 936 - 946. 15/03/2015.
Type of production: Scientific paper
Position of signature: 20
Total no. authors: 20 **Corresponding author:** Yes
- 85** A Olvera; S Pérez-Álvarez; J Ibarrodo; C Ganoza; JR Lama; A Lucchetti; S Cate; W Hildebrand; N Bernard; L Gomez; J Sanchez; C Brander. The HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with high population frequency drive rate of HIV disease progression. *AIDS*. 29(5), pp. 507 - 517. 13/03/2015.
Type of production: Scientific paper
- 86** S Perez-Alvarez; G Gómez; C Brander. FARMS: A New Algorithm for Variable Selection. *Biomed Res Int*. 2015:319797, 06/03/2015.
Type of production: Scientific paper **Format:** Journal
- 87** G Hancock; H Yang; E Yorke; E Wainwright; V Bourne; A Frisbee; TL Payne; M Berrong; G Ferrari; D Chopera; T Hanke; B Mothe; C Brander; MJ McElrath; A McMichael; N Goonetilleke; GD Tomaras; N Frahm; L Dorrell. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. *PLOS Pathog*. 11(02):e1004658, 27/02/2015.
Type of production: Scientific paper **Format:** Journal
- 88** B Mothe; N Climent; M Plana; M Rosàs; JL Jiménez; MÁ Muñoz-Fernández; MC Puertas; J Carrillo; N Gonzalez; A León; J Pich; JA Arnaiz; JM Gatell; B Clotet; J Blanco; J Alcamí; J Martinez-Picado; C Alvarez-Fernández; S Sánchez-Palomino; AC Guardo; J Peña; JM Benito; N Rallón; CE Gómez; B Perdiguero; J García-Arriaza; M Esteban; JC López Bernaldo de Quirós; C Brander; F García; RISVAC03 Study Group. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. *J Antimicrob Chemother*. 70(6), 26/02/2015.
Type of production: Scientific paper **Format:** Journal



- 89** B Mothe; X Hu; A Llano; M Rosati; A Olvera; V Kulkarni; A Valentin; C Alicea; GR Pilkington; NY Sardesai; M Rocafort; M Crespo; J Carrillo; A Marco; JI Mullins; L Dorrell; T Hanke; B Clotet; GN Pavlakis; BK Felber; C Brander. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. *J Transl Med.* 13 - 60, 15/02/2015.
Type of production: Scientific paper **Format:** Journal
Position of signature: 21
Total no. authors: 21 **Corresponding author:** Yes
- 90** JC Yaciuk; M Skaley; W Bardet; F Schafer; D Mojsilovic; S Cate; CJ Stewart; C McMurtrey; KW Jackson; R Buchli; A Olvera; S Cedeño; B Mothe; C Brander; JT West; WH Hildebrand. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells. *J Virol.* 88(22), pp. 12992 - 13004. 01/11/2014.
Type of production: Scientific paper
- 91** A Olvera; C Ganoza; S Pérez-Álvarez; W Hildebrand; J Sanchez; C Brander. HLA-B*35-PX and HLA-B*35-PY subtype differentiation does not predict observed differences in level of HIV control in a Peruvian MSM cohort. *AIDS.* 28(15), pp. 2323 - 2325. 24/09/2014.
Type of production: Scientific paper
- 92** E Pauls; A Ruiz; R Badia; M Permanyer; A Gubern; E Riveira- Muñoz; J Torres-Torronteras; M Álvarez; B Mothe; M Crespo; C Brander; L Menéndez-Arias; B Clotet; OT Keppler; R Martí; F Posas; E Ballana; JA Esté. Cell cycle control and HIV-1 susceptibility are linked by a CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. *Journal Immunology.* 193(4):97, pp. 1988 - 1997. 15/08/2014.
Type of production: Scientific paper **Format:** Journal
- 93** J Dalmau; M Rotger; I Erkizia; A Rauch; P Reche; M Pino; A Esteve; E Palou; C Brander; R Paredes; P Phung; B Clotet; A Telenti; J Martinez-Picado; JG Prado; The CoRP Study Group. Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. *AIDS.* 28(9), pp. 1261 - 1272. 01/07/2014.
Type of production: Scientific paper **Format:** Journal
- 94** E Riveira-Muñoz; A Ruiz; E Pauls; M Permanyer; R Badia; B Mothe; M Crespo; B Clotet; C Brander; E Ballana; J Este. Increased expression of SAMHD1 in a subset of HIV-1 Elite Controllers. *Journal of Antimicrobial Chemotherapy.* in press, 30/06/2014.
Type of production: Scientific paper **Format:** Journal
- 95** F Bohne; MC Londoño; C Benítez; R Miquel; M Martínez-Llordella; C Russo; C Ortiz; E Bonaccorsi-Riani; C Brander; T Bauer; U Protzer; E Jaekel; R Taubert; X Forns; M Navasa; M Berenguer; A Rimola; JJ Lozano; A Sánchez-Fueyo. HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans. *Science Translational Medicine.* 6(242):242ra81, 25/06/2014.
Type of production: Scientific paper **Format:** Journal
- 96** NH van Teijlingen; A Hölzemer; C Körner; WF García-Beltrán; JL Schafer; L Fadda; TJ Suscovich; C Brander; M Carrington; DT Evans; D van Baarle; M Altfeld. Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03: 04 and modulate primary natural killer cell function. *AIDS.* 28(10), pp. 1399 - 1408. 19/06/2014.
Type of production: Scientific paper **Format:** Journal
- 97** H Klooverpris; E Adland; M Koyanagi; A Stryhn; M Harndahl; PC Matthews; R Shapiro; B Walker; T Ndung'u; C Brander; M Takiguchi; S Buus; PJ Goulder. HIV subtype influences HLA-B*07:02-associated HIV disease outcome. *AIDS Res Hum Retroviruses.* 30(5), pp. 468 - 475. 01/05/2014.
Type of production: Scientific paper **Format:** Journal



- 98** RP Payne; S Branch; H Kløverpris; PC Matthews; CK Koofhethile; T Strong; E Adland; E Leitman; J Frater; T Ndung'u; E Hunter; R Haubrich; B Mothe; A Edwards; L Riddell; F Chen; PR Harrigan; ZL Brumme; S Mallal; M John; JP Jooste; R Shapiro; SG Deeks; BD Walker; C Brander; C Landis; JM Carlson; JG Prado; PJ Goulder. Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints. *J Virol.* 88(9), pp. 4668 - 4678. 05/2014.
Type of production: Scientific paper **Format:** Journal
- 99** A Kawana-Tachikawa; JM Llibre; I Bravo; R Escrig; B Mothe; J Puig; MC Puertas; J Martinez-Picado; J Blanco; C Manzardo; JM Miro; A Iwamoto; AL Pozniak; JM Gatell; B Clotet; C Brander; MARAVIBOOST Investigators. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. *Plos One.* 9(1):e87334, 27/01/2014.
Type of production: Scientific paper **Format:** Journal
- 100** V Kulkarni; A Valentin; M Rosati; C Alicea; AK Singh; R Jalah; KE Broderick; NY Sardesai; S Le Gall; B Mothe; C Brander; M Rolland; JI Mullins; GN Pavlakis; BK Felber. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. *Plos One.* 9(1):e86254, 23/01/2014.
Type of production: Scientific paper **Format:** Journal
- 101** E Loggi; FK Bihl; C Cursaro; C Granieri; S Galli; L Brodosi; G Furlini; M Bernardi; C Brander; P Andreone. Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. *Plos One.* 8(6):e65327, 04/06/2013.
Type of production: Scientific paper **Format:** Journal
- 102** M Ruiz-Riol; B Mothe; R T Gandhi; N Bhardwaj; D T Scadden; V Sanchez-Merino; C Brander. Influenza, but not HIV-specific CTL epitopes elicit delayed-type hypersensitivity (DTH) reactions in humans. *Eur J Immunol.* 43(6), pp. 1545 - 1554. 06/2013.
Type of production: Scientific paper
- 103** VA Chereshnev; G Bocharov; S Bazhan; B Bachmetyev; I Gainova; V Likhoshvai; JM Argilaguete; JP Martinez; JA Rump; B Mothe; C Brander; A Meyerhans. Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective. *Int Rev Immunol.* 32(3), pp. 282 - 306. 06/2013.
Type of production: Scientific paper **Format:** Journal
Position of signature: 11
Total no. authors: 12 **Corresponding author:** No
- 104** L Micco; D Peppia; E Loggi; A Schurich; L Jefferson; C Cursaro; AM Panno; M Bernardi; C Brander; F Bihl; P Andreone; MK Maini. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. *Journal of Hepatology.* 58(2), pp. 225 - 233. 02/2013.
Type of production: Scientific paper **Format:** Journal
- 105** A Llano; J Carrillo; B Mothe; L Ruiz; S Marfil; E García; E Yuste; V Sánchez; B Clotet; J Blanco; C Brander. Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. *J Transl Med.* 11, pp. 48. 02/2013.
Type of production: Scientific paper **Format:** Journal
- 106** O Gasser; C Brander; M Wolbers; N Brown; A Rauch; H Günthard; M Battegay. Expansion of interferon- γ -secreting HIV-specific T cells during successful antiretroviral therapy. *HIV Med.* 4, pp. 241 - 246. 2013.
Type of production: Scientific paper **Format:** Journal



- 107** V Kulkarni; M Rosati; A Valentin; B Ganneru; AK Singh; J Yan; M Rolland; C Alicea; RK Beach; GM Zhang; S Le Gall; KE Broderick; NY Sardesai; D Heckerman; B Mothe; C Brander; DB Weiner; JI Mullins; GN Pavlakis; BK Felber. HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. *PLoS One*. 8(3), pp. e60245. 2013.
Type of production: Scientific paper **Format:** Journal
- 108** E Ballana; E Riveira-Munoz; C Pou; V Bach; M Parera; M Noguera; JR Santos; R Badia; M Casadellà; B Clotet; R Paredes; MA Martínez; C Brander; JA Esté. HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-?32/?32. *Immunobiology*. 4, pp. 543 - 547. 2013.
Type of production: Scientific paper **Format:** Journal
- 109** P C Matthews; M Koyanagi; H N Kløverpris; M Harndahl; A Stryhn; T Akahoshi; H Gatanaga; S Oka; C Juarez Molina; H Valenzuela Ponce; S Avila Rios; D Cole; J Carlson; R P Payne; A Ogwu; A Bere; T Ndung'u; K Gounder; F Chen; L Riddell; G Luzzi; R Shapiro; C Brander; B Walker; A K Sewell; G Reyes Teran; D Heckerman; E Hunter; S Buus; M Takiguchi; P J Goulder. Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. *J Virol*. 86(23), pp. 12643 - 12654. 12/2012.
Type of production: Scientific paper
- 110** A Llano; C Brander. Mechanisms of Abacavir hyperreactivity. *Cell Res*. 22(12), pp. 1637 - 1639. 12/2012.
Type of production: Scientific paper
- 111** L Micco; D Peppia; E Loggi; A Schurich; L Jefferson; C Cursaro; A M Panno; M Bernardi; C Brander; F Bihl; P Andreone; M K Maini. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. *J Hepatol*. Epub ahead of print, 06/10/2012.
Type of production: Scientific paper
- 112** E Ballana; A Ruiz-de Andres; B Mothe; E Ramirez de Arellano; F Aguilar; R Badia; E Grau; B Clotet; M del Val; C Brander; J A Esté. Differential prevalence of the HLA-C -35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. *Immunobiology*. 217(9), pp. 889 - 894. 09/2012.
Type of production: Scientific paper
- 113** O Gasser; C Brander; M Wolbers; N Brown; A Rauch; H Günthard; M Battegay; C Hess. Expansion of interferon-?-secreting HIV-specific T cells during successful antiretroviral therapy. *HIV Med*. Epub ahead of print, 30/08/2012.
Type of production: Scientific paper
- 114** E Ballana; E Riveira-Munoz; C Pou; V Bach; M Parera; M Noguera; J R Santos; R Badia; M Casadellà; B Clotet; R Paredes; M A Martínez; C Brander; J A Esté. HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-?32/?32. *Immunobiology*. Epub ahead of print, 28/06/2012.
Type of production: Scientific paper
- 115** M A Brockman; D R Chopera; A Olvera; C J Brumme; J Sela; T J Markle; E Martin; J M Carlson; A Q Le; R McGovern; P K Cheung; A D Kelleher; H Jessen; M Markowitz; E Rosenberg; N Frahm; J Sanchez; S Mallal; M John; P R Harrigan; D Heckerman; C Brander; B D Walker; Z L Brumme. Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity. *J Virol*. 86(12), pp. 6913 - 6923. 06/2012.
Type of production: Scientific paper
- 116** C R Fumaz; M Gonzalez-Garcia; X Borrás; J A Muñoz-Moreno; N Perez-Alvarez; B Mothe; C Brander; M J Ferrer; J Puig; A Llano; J Fernandez-Castro; B Clotet. Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. *Brain Behav Immun*. 26(4), pp. 568 - 572. 05/2012.
Type of production: Scientific paper



- 117** S 145. Sabbah; Y J Jagne; J Zuo; T de Silva; MM Ahasan; C Brander; S Rowland-Jones; K L Flanagan; A D Hislop. T-cell immunity to Kaposi's sarcoma-associated herpesvirus: recognition of primary effusion lymphoma with LANA-specific CD4+ T cells. *Blood*. 119(9), pp. 2083 - 2092. 01/03/2012.
Type of production: Scientific paper
Position of signature: 6
Total no. authors: 9 **Corresponding author:** No
- 118** E Loggi; L Micco; G Ercolani; A Cucchetti; F K Bihl; G L Grazi; S Gitto; A Bontadini; M Bernardi; P Grossi; A N Costa; A D Pinna; C Brander; P Andreone. Liver Transplantation from Hepatitis B Surface Antigen Positive Donors: A Safe Way to Expand the Donor Pool. *J Hepatol*. 56(3), pp. 579 - 585. 03/2012.
Type of production: Scientific paper
- 119** B Mothe; A Llano; J Ibarrondo; J Zamarreño; M Schiaulini; C Miranda; M Ruiz; C T Berger; M J Herrero; E Palou; M Plana; M Rolland; A Khatri; D Heckerman; F Pereyra; B D Walker; D Weiner; R Paredes; B Clotet; B K Felber; G N Pavlakis; J I Mullins; C Brander. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. *PLoS One*. 7(1), pp. e29717. 2012.
Type of production: Scientific paper
- 120** M Pernas; C Casado; C Arcones; A Llano; V Sánchez-Merino; B Mothe; J L Vicario; E Grau; L Ruiz; J Sanchez; A Telenti; E Yuste; C Brander; C Lopez-Galindez. Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP Elite controller. *PLoS One*. 7(2), pp. e31928. 2012.
Type of production: Scientific paper
- 121** M R Henn; C L Boutwell; P Charlebois; N J Lennon; K A Power; A R Macalalad; A M Berlin; C M Malboeuf; E M Ryan; S Gnerre; M C Zody; R L Erlich; L M Green; A Berical; Y Wang; M Casali; H Streeck; A K Bloom; T Dudek; D Tully; R Newman; K L Axten; A D Gladden; L Battis; M Kemper; Q Zeng; T P Shea; S Gujja; C Zedlack; O Gasser; C Brander; C Hess; H F Günthard; Z L Brumme; C J Brumme; S Bazner; J Rychert; J P Tinsley; K H Mayer; E Rosenberg; F Pereyra; J Z Levin; S K Young; H Jessen; M Altfeld; B W Birren; B D Walker; T M Allen. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. *PLoS Pathog*. 8(3), pp. e1002529. 2012.
Type of production: Scientific paper
- 122** B Mothe; A Llano; J Ibarrondo; M Daniels; C Miranda; J Zamarreño; V Bach; R Zuniga; S Pérez-Álvarez; C T Berger; M C Puertas; J Martinez- Picado; M Rolland; M Farfan; J J Szinger; W H Hildebrand; O O Yang; V Sanchez-Merino; C J Brumme; Z L Brumme; D Heckerman; T M Allen; J I Mullins; G Gómez; P J Goulder; B D Walker; J M Gatell; B Clotet; B T Korber; J Sanchez; C Brander. Definition of the viral targets of protective HIV-1-specific T cell responses. *J Transl Med*. 9(1), pp. 208. 07/12/2011.
Type of production: Scientific paper
- 123** C T Berger; N Frahm; D A Price; B Mothe; M Ghebremichael; K L Hartman; L M Henry; J M Brenchley; L E Ruff; V Venturi; F Pereyra; J Sidney; A Sette; D C Douek; B D Walker; D E Kaufmann; C Brander. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. *J Virol*. 85(18), pp. 9334 - 9345. 09/2011.
Type of production: Scientific paper
Position of signature: 17
Total no. authors: 17 **Corresponding author:** Yes
- 124** M C Iglesias; J R Almeida; S Fastenackels; D J van Bockel; M Hashimoto; V Venturi; E Gostick; A Urrutia; L Wooldridge; M Clement; S Gras; P G Wilmann; B Autran; A Moris; J Rossjohn; M P Davenport; M Takiguchi; C Brander; D C Douek; A D Kelleher; D A Price; V Appay. Escape from highly effective public CD8+ T-cell clonotypes by HIV. *Blood*. 118(8), pp. 2138 - 2149. 25/08/2011.
Type of production: Scientific paper
Position of signature: 18



Total no. authors: 22

- 125** C Gil; N Climent; F García; C Hurtado; S Nieto-Márquez; A León; M T García; C Rovira; L Miralles; J Dalmau; T Pumarola; M Almela; J Martínez-Picado; J D Lifson; L Zamora; J M Miró; C Brander; B Clotet; T Gallart; J M Gatell. Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. *Vaccine*. 29(34), pp. 5711 - 5724. 05/08/2011.
Type of production: Scientific paper
- 126** J Greenbaum; J Sidney; J Chung; C Brander; B Peters; A Sette. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. *Immunogenetics*. 63(6), pp. 325 - 335. 06/2011.
Type of production: Scientific paper
Position of signature: 4
Total no. authors: 6 **Corresponding author:** No
- 127** P Kanya; S Boulet; C M Tsoukas; J P Routy; R Thomas; P Côté; M R Boulassel; J G Baril; C Kovacs; S A Migueles; M Connors; T J Suscovich; C Brander; C L Tremblay; N Bernard. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1**h*/**y* and HLA-B*57. *J Virol*. 85(12), pp. 5949 - 5960. 06/2011.
Type of production: Scientific paper
- 128** M Rolland; N Frahm; D C Nickle; N Jojic; W Deng; T M Allen; D E Heckerman; C Brander; J I Mullins. Increased breadth and depth of cytotoxic T lymphocytes responses against HIV-1-B Nef by inclusion of epitope variant sequences. *PLoS One*. 6(3), pp. e17969. 28/03/2011.
Type of production: Scientific paper
- 129** O Gasser; G Zenhausern; G Hönger; C Brander; C Hess. . Immunosuppressive drugs asymmetrically impact circulating T cell counts and function. *Scand J Immunol*. 73(1), pp. 76 - 77. 2011.
Type of production: Scientific paper
- 130** S Buranapraditkun; U Hempel; P Pitakpolrat; R L Allgaier; P Thantivorasit; S I Lorenzen; S Sirivichayakul; W H Hildebrand; M Altfeld; C Brander; B D Walker; P Phanuphak; P Hansasuta; S L Rowland-Jones; T M Allen; K Ruxrungtham. A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais. *PLoS One*. 6(8), pp. e23603. 2011.
Type of production: Scientific paper
- 131** F Garcia; N Climent; L Assoumou; C Gil; N Gonzalez; J Alcamí; A Leon; J Romeu; J Dalmau; J Martínez-Picado; J Lifson; B Autran; D Costagliola; B Clotet; J M Gatell; M Plana; T Gallart. A therapeutic dendritic cell-based vaccine for HIV-1 infection. *J Inf Dis*. 203, pp. 473 - 478. 2011.
Type of production: Scientific paper
- 132** T Daikeler; G Hoenger; I Oehri; A Tyndall; A Gratwohl; C Brander; T Klimkait; O Gasser; C Hess. Dominant Epstein-Barr virus-specific T-cell responses are maintained during moderate and intense immunosuppressive treatment. *Ann Rheum Dis*. 70(2), pp. 395 - 396. 2011.
Type of production: Scientific paper
Position of signature: 6
Total no. authors: 9 **Corresponding author:** No
- 133** R Grenningloh; N Frahm; C Brander; H I-Cheng. Ets-1 maintains CD127 expression in peripheral T cells and is downregulated in CD127-negative T cells during HIV infection. *J Immunol*. 186(2), pp. 969 - 976. 2011.
Type of production: Scientific paper
Position of signature: 3
Total no. authors: 4 **Corresponding author:** No



- 134** A Leslie; P C Matthews; J Listgarten; J M Carlson; C Kadie; T Ndung'u; C Brander; H Coovadia; B D Walker; D Heckerman; P J Goulder. Additive Contribution of HLA Class I Alleles in the Immune Control of HIV-1 Infection. *J Virol.* 84(19), pp. 9879 - 9888. 10/2010.
Type of production: Scientific paper
- 135** M Rolland; J M Carlson; S Manochewa; J V Swain; E Lanxon-Cookson; W Deng; C M Rousseau; D N Raugi; G H Learn; B S Maust; H Coovadia; T Ndung'u; P J Goulder; B D Walker; C Brander; D E Heckerman; J I Mullins. Amino-Acid Co-Variation in HIV-1 Gag Subtype C: HLA-Mediated Selection Pressure and Compensatory Dynamics. *PLoS One.* 5(9), pp. pii: e12463. 01/09/2010.
Type of production: Scientific paper
- 136** C T Berger; J M Carlson; C J Brumme; K L Hartman; Z L Brumme; L M Henry; P C Rosato; A Piechocka-Trocha; M A Brockman; P R Harrigan; D Heckerman; D E Kaufmann; C Brander. Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. *J Exp Med.* 207(1), pp. 61 - 75. 18/01/2010.
Type of production: Scientific paper
Position of signature: 13
Total no. authors: 13
Corresponding author: Yes
- 137** S C Dollard; L M Butler; A M Graves Jones; J H Mermin; M Chidzonga; T Chipato; C H Shiboski; C Brander; A Mosam; P Kiepiela; W Hladik; J N Martin. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-saharan Africa: Insights on the origin of the "KS Belt". *Int J Cancer.* 127, pp. 2395 - 2401. 2010.
Type of production: Scientific paper
- 138** Z Brumme; B Wang; K Nair; C Brumme; C de Pierres; S Reddy; B Julg; E Moodley; C Thobakgale; Z Lu; M van der Stok; K Bishop; Z Mncube; F Chonco; Y Yuki; N Frahm; C Brander; M Carrington; K Freedberg; P Kiepiela; P Goulder; B Walker; T Ndung'u; E Losina. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. *Clin Infect Dis.* 49(6), pp. 956 - 964. 15/09/2009.
Type of production: Scientific paper
- 139** F Bihl; C Berger; J Chisholm; L M Henry; B Bertischi; A Trojan; D Nadal; R Speck; M Flepp; C Brander; N J Mueller; Swiss HIV Cohort Study. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. *AIDS.* 23(14), pp. 1918 - 1922. 10/09/2009.
Type of production: Scientific paper
- 140** Z L Brumme; M John; J M Carlson; C J Brumme; D Chan; M A Brockman; L C Swenson; I Tao; S Szeto; P Rosato; J Sela; C M Kadie; N Frahm; C Brander; D W Haas; S A Riddler; R Haubrich; B D Walker; P R Harrigan; D Heckerman; S Mallal. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. *PLoS One.* 4(8), pp. e6687. 19/08/2009.
Type of production: Scientific paper
- 141** L M Butler; G Dorsey; W Hladik; P J Rosenthal; C Brander; T B Neilands; G Mbisa; D Whitby; P Kiepiela; A Mosam; S Mzolo; S C Dollard; J N Martin. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. *J Infect Dis.* 200(3), pp. 430 - 438. 01/08/2009.
Type of production: Scientific paper
- 142** D Brainard; A M Tager; N Frahm; S Westmoreland; W Hart; H Knight; Q Eichbaum; B D Walker; G Freeman; Y Yang; M Sykes; C Brander; A D Luster. HIV infection in a novel humanized mouse results in generalized immune activation and virus-specific adaptive immune responses. *J Virol.* 83(14), pp. 7305 - 7321. 07/2009.
Type of production: Scientific paper



- 143** Y Kawashima; K Pfafferott; J Frater; P Matthews; R Payne; M Addo; H Gatanaga; M Fujiwara; A Hachiya; H Koizumi; N Kuse; S Oka; A Duda; A Prendergast; H Crawford; A Leslie; Z Brumme; C Brummer; T M Allen; C Brander; R Kaslow; J Tang; E Hunter; S Allen; J Mulenga; S Branch; T Roach; M John; S Mallal; A Ogwu; R Shapiro; J G Prado; O G Pybus; P Klenerman; T Ndung'u; R Phillips; D Heckerman; R Harrign; B D Walker; M Takiguchi; P Goulder. HIV adaptation to HLA I. *Nature*. 458(7238), pp. 641 - 645. 02/04/2009.
Type of production: Scientific paper
- 144** o Gasser; F Bihl; S Sanghavi; C Rinaldo; D Rowe; S Schaub; J Steiger; D Stablein; M Roland; P Stock; C Hess; C Brander. Sustained anti-viral immune responsiveness in HIV infected solid organ transplant recipients. *Am J Transplant*. 9(4), pp. 794 - 803. 04/2009.
Type of production: Scientific paper
- 145** E Loggi; F Bihl; J V Chisholm; M Biselli; A Bontadini; G Vitale; G Ercolani; G L Grazi; A D'Pinna; M Bernardi; C Brander; P Andreone. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graf. *J Hepatol*. 50(3), pp. 625 - 630. 03/2009.
Type of production: Scientific paper
- 146** T Miura; M A Brockman; A Schneidewind; M Lobritz; F Pereyra; A Rathod; B L Block; Z L Brumme; C J Brumme; B Baker; A C Rothchild; B Li; A Trocha; E Cutrell; N Frahm; C Brander; I Toth; E J Arts; T M Allen; B D Walker. HLA-B57/B*5801 HIV-1 elite controllers select for rare Gag variants associated with reduced viral replication capacity and strong CTL recognition. *J Virol*. 83(6), pp. 2743 - 2755. 03/2009.
Type of production: Scientific paper
- 147** C M Rousseau; D W Lockhart; J Listgarten; S N Maley; C Kadie; G H Learn; D C Nickle; D E Heckerman; W Deng; C Brander; T Ndung'u; H Coovadia; P J Goulder; B T Korber; B D Walker; J I Mullins. Rare HLA drive additional HIV evolution compared to more frequent alleles. *AIDS Res Hum Retroviruses*. 25(3), pp. 297 - 303. 03/2009.
Type of production: Scientific paper
- 148** Y E Wang; B Li; J M Carlson; H Streeck; A D Gladden; R Goodman; A Schneidewind; K A Power; I Toth; N Frahm; G Alter; C Brander; M Carrington; B D Walker; M Altfeld; D Heckerman; T M Allen. Protective HLA Class I Alleles Restricting Acute-Phase CD8+ T Cell Responses are Associated with Viral Escape Mutations Located in Highly Conserved Regions of HIV-1. *J Virol*. 83(4), pp. 1845 - 1855. 02/2009.
Type of production: Scientific paper
- 149** J Dalmau; M C Puertas; M Azuara; A Mariño; N Frahm; N Izquierdo-Useros; M J Buzón; R Paredes; L Matas; C Brander; C Rodrigo; B Clotet; J Martinez-Picado. Severe primary sexually transmitted HIV-infection due to dual-tropic HIV-1. *Clin Inf Diseases*. 48(2), pp. 229 - 238. 2009.
Type of production: Scientific paper
- 150** A T Tan; E Loggi; C Boni; A Chia; A Gehring; K S R Sastry; V Goh; P Fiscaro; P Androne; C Brander; S G Lim; C Ferrari; F Bihl; A Bertoletti. Host Ethnicity and virus genotype shape the HBV-specific T cell repertoire. *J Virol*. 82(22), pp. 10986 - 10997. 11/2008.
Type of production: Scientific paper
Position of signature: 10
Total no. authors: 14
- 151** P C Matthews; A Prendergast; A Leslie; H Crawford; R Payne; C Rousseau; M Rolland; I Honeyborne; J Carlson; C Kadie; C Brander; K Bishop; N Mlotshwa; J I Mullins; H Coovadia; T Ndung'u; B D Walker; D Heckerman; P J Goulder. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. *J Virol*. 82(17), pp. 8548 - 8559. 09/2008.
Type of production: Scientific paper



- 152** H Streeck; B Li; A Poon; A Schneidewind; A D Gladden; K A Power; S B Bazner; C Brander; R Zuniga; E S Rosenberg; S Frost; M Altfeld; T M Allen. Immune driven HIV recombination and loss of control following superinfection. *J Exp Med.* 205(8), pp. 1789 - 1796. 04/08/2008.
Type of production: Scientific paper
- 153** Z L Brumme; I Tao; S Szeto; C J Brumme; J M Carlson; D Chan; C Kadie; N Frahm; C Brander; R S Hogg; B D Walker; D Heckerman; P R Harrigan. Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. *AIDS.* 22(11), pp. 1277 - 1286. 11/07/2008.
Type of production: Scientific paper
- 154** A Schneidewind; M A Brockman; J Sidney; Y E Wang; H Chen; T J Suscovich; B Li; R I Adam; R L Allgaier; B R Mothé; T Kuntzen; C Oniangue-Ndza; X G Yu; A Trocha; C Brander; A Sette; B D Walker; T M Allen. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. *J Virol.* 82(11), pp. 5594 - 5605. 06/2008.
Type of production: Scientific paper
- 155** F Bihl; E Loggi; J V Chisholm; M Biselli; M C Morelli; N A Terrault; M Bernardi; A Bertoletti; P Andreone; C Brander. Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection. *Liver Transpl.* 14(4), pp. 478 - 485. 04/2008.
Type of production: Scientific paper
- 156** D Yerly; D Heckermann; T M Allen; J V Chisholm; K Faircloth; J Timm; W J Pichler; A Cerny; C Brander. Increased CTL epitope variant cross-recognition is associated with HCV clearance. *J Virol.* 82(6), pp. 3147 - 3153. 03/2008.
Type of production: Scientific paper
- 157** A Joseph; J H Zheng; A Follenzi; T DeLorenzo; K Sango; J Hyman; K Chen; A Trocha; C Brander; E Hooijberg; D A Vignali; B D Walker; H Goldstein. Inhibition of In Vivo HIV Replication by Peripheral Blood CD8 T Lymphocytes Converted into HIV-specific CTL by Lentiviral-mediated TCR Gene Transduction. *J Virol.* 82(6), pp. 3078 - 3089. 03/2008.
Type of production: Scientific paper
- 158** N Frahm; D Nickle; C H Linde; H S Hewitt; R L Allgaier; L M Heath; N V Brown; M T Zaman; E Pae; R Zuñiga; A Lucchetti; J Sanchez; St John M A; T Roach; P Kiepiela; P J R Goulder; B D Walker; T Leitner; T M Allen; B T Korber; J I Mullins; C Brander. Increased detection of HIV-specific T cell responses by combination of centralized sequences with comparable in vitro immunogenicity. *AIDS.* 22(4), pp. 447 - 456. 19/02/2008.
Type of production: Scientific paper
- 159** J Sidney; B Peters; N Frahm; C Brander; A Sette. HLA Supertypes: a revised and updated classification. *BMC Immunol.* 22/01/2008.
Type of production: Scientific paper
- 160** M Rolland; D Heckerman; W Deng; C M Rousseau; P J R Goulder; B D Walker; C Brander; J I Mullins. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. *PLoS ONE.* 3(1), pp. e1424. 09/01/2008.
Type of production: Scientific paper
- 161** D Yerly; D Heckermann; T M Allen; T Suscovich; W J Pichler; A Cerny; C Brander. Design, expression and processing of epitomized HCV encoded CTL epitopes. *J Immunol.* 181(9), pp. 6361 - 6370. 2008.
Type of production: Scientific paper



Type of production: Scientific paper

- 172** A J Frater; H Brown; A Oxenius; H F Gunthard; B Hirschel; N Robinson; A J Leslie; R Payne; H Crawford; A Prendergast; C Brander; P Kiepiela; B D Walker; P J Goulder; A McLean. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. *J Virol.* 81(12), pp. 6742 - 6751. 06/2007.
Type of production: Scientific paper
- 173** F Bihl; M Narayan; J C Chisholm; L M Henry; E Brown; T M Welzel; D E Kaufmann; T Zaman; S Dollard; J N Martin; F Wang; D T S Scadden; K Kaye; C Brander. Lytic and latent antigens of human γ -Herpesviruses EBV and KSHV induce T cell responses with similar functional properties and memory phenotypes. *J Virol.* 81(9), pp. 4904 - 4908. 05/2007.
Type of production: Scientific paper
Position of signature: 14
Total no. authors: 14
- 174** I Honeyborne; A Prendergast; F Pereyra; A Leslie; H Crawford; R Payne; S Reddy; K Bishop; E Moodley; K Nair; M van der Stok; N McCarthy; C M Rousseau; M Addo; J I Mullins; C Brander; P Kiepiela; B D Walker; P J Goulder. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. *J Virol.* 81(7), pp. 3667 - 3672. 04/2007.
Type of production: Scientific paper
- 175** O Gasser; F Bihl; B Loggi; I Steffen; H H Hirsch; H Günthard; B D Walker; C Brander; M Battegay; C Hess. Epstein-Barr virus-selective immuno-deficiency in HIV-infected individuals developing primary central nervous system lymphoma; a case-control study. *PLOS Medicine.* 4(3), pp. e96. 27/03/2007.
Type of production: Scientific paper
Position of signature: 8
Total no. authors: 10
- 176** T Bhattacharya; M Daniels; D Heckerman; B Foley; N Frahm; C Kadie; J Carlson; K Yusim; B McMahon; B Gaschen; S Mallal; J I Mullins; D C Nickle; J Herbeck; C Rousseau; G H Learn; T Miura; C Brander; B D Walker; B Korber. Founder Effects in Population Based Assessment of HIV Polymorphisms and HLA Allele Associations. *Science.* 315(5818), pp. 1583 - 1586. 16/03/2007.
Type of production: Scientific paper
- 177** X G Yu; M Lichterfeld; S Chetty; K L Williams; S K Mui; T Miura; N Frahm; M E Feeney; Y Tang; F Pereira; M X LaBute; K Pfafferoth; A Leslie; H Crawford; R Allgaier; W Hildebrand; R Kaslow; C Brander; T M Allen; E S Rosenberg; P Kiepiela; M Vajpayee; P A Goepfert; M Altfeld; P J R Goulder; B D Walker. Mutually exclusive T cell receptor induction and differential susceptibility to HIV-1 mutational escape associated with a two amino acid difference between HLA class I subtypes. *J Virol.* 81(4), pp. 1619 - 1631. 02/2007.
Type of production: Scientific paper
- 178** P Kiepiela; C Thobakgale; D Ramduth; I Honeyborne; E Moodley; Z Mncube; N Mkhwanazi; N Khan; C Brander; C Rousseau; J I Mullins; H Coovadia; B T Korber; D Heckerman; B D Walker; P J R Goulder. Discordant control of HIV infection associated with Gag and Env-specific CD8 T cell responses. *Nat Med.* 13(1), pp. 46 - 53. 01/2007.
Type of production: Scientific paper
- 179** K Schaubert; D Price; N Frahm; O O Yang; J Li; E Paul; B Majumder; V Ayyavoo; E Gostick; F M Marincola; A K Sewell; M Altfeld; J M Brenchley; D Douek; C Brander; H Goldstein; J Kan-Mitchell. A Diversely Avid CD8+ T Cell repertoire contributes to the subdominant status of the HLA-A2-restricted HIV-1 p2419-27 epitope. *J. Immunol.* 178, pp. 7756 - 7766. 2007.
Type of production: Scientific paper



- 180** E Assarson; J Sidney; C Oseroff; V Pasquetto; H H Bui; N Frahm; C Brander; B Peters; H Grey; A Sette. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. *J Immunol.* 178(12), pp. 7890 - 7901. 2007.
Type of production: Scientific paper
- 181** J Timm; M Neukamm; T Kuntzen; R T Chung; C Brander; G M Lauer; B D Walker; T M Allen. Characterization of Full Length HCV Genotype 4 Sequences. *J Viral Hepat.* 14(5), pp. 330 - 337. 2007.
Type of production: Scientific paper
- 182** H Crawford; J G Prado; A Leslie; S Hue; I Honeyborne; S Reddy; M van der Stok; Z Mncube; C Brander; C Rousseau; J I Mullins; R Kaslow; P Goepfert; S Allen; E Hunter; J Mulenga; P Kiepiela; B D Walker; P J Goulder. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703 restricted Gag epitope in chronic HIV infection. *J. Virology.* 81, pp. 8346 - 8351. 2007.
Type of production: Scientific paper
- 183** D M Brainard; A M Tager; J Misdraji; M Lichterfeld; R Draenert; C Brander; B D Walker; A D Luster. Decreased CXCR3 + CD8 T-cells in advanced HIV infection suggests a homing defect contributes to CTL dysfunction. *J Virol.* 81, pp. 8439 - 8450. 2007.
Type of production: Scientific paper
- 184** C M Rousseau; G H Learn; T Bhattacharya; D C Nickle; D Heckerman; S Chetty; C Brander; P J Goulder; B D Walker; P Kiepiela; B T Korber; J I Mullins. Extensive Intra-subtype. Recombination among HIV-1 subtype C genomes. *J Virol.* 81(9), pp. 4492 - 4500. 2007.
Type of production: Scientific paper
Position of signature: 7
Total no. authors: 12
- 185** F Bihl; A Mosam; J V Chisholm; L M Henry; S Dollard; N Nene; P Mkhize; E Cassol; T Page; N Mueller; P Kiepiela; S Cassol; J N Martin; H M Coovadia; D T Scadden; C Brander. KSHV-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C infected individuals with Kaposi's Sarcoma. *AIDS.* 21(10), pp. 1245 - 1252. 2007.
Type of production: Scientific paper
Position of signature: 16
Total no. authors: 16
- 186** G Alter; T J Suscovich; N Teigen; A Meier; H Streeck; C Brander; M Altfeld. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. *J Immunol.* 178(12);, pp. 7658 - 7666. 2007.
Type of production: Scientific paper
- 187** E J Wherry; C L Day; R Draenert; J D Miller; P Kiepiela; T Woodberry; C Brander; M Addo; P Klenerman; R Ahmed; B D Walker. HIV-specific CD8 T cells express low levels of IL-7Ralpha: Implications for HIV-specific T cell memory. *Virology.* 353(2), pp. 366 - 373. 30/09/2006.
Type of production: Scientific paper
- 188** C M Rousseau; B A Birditt; A R McKay; J N Stoddard; T C Lee; S McLaughlin; S W Moore; N Shindo; G H Learn; B T Korber; C Brander; P J Goulder; P Kiepiela; B D Walker; J I Mullins. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. *J Virol Methods.* 136(1-2), pp. 118 - 125. 09/2006.
Type of production: Scientific paper



- 189** M Lichterfeld; K L Williams; S K Mui; S S Shah; B R Mothe; A Sette; A Kim; M N Johnston; N Burgett; N Frahm; D Cohen; C Brander; E S Rosenberg; B D Walker; M Altfeld; X G Yu. T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily. *Int Immunol.* 18(7), pp. 1179 - 1188. 07/2006.
Type of production: Scientific paper
- 190** N Frahm; P Kiepiela; S Adams; C H Linde; H S Hewitt; K Sango; M E Feeney; M M Addo; M Lichterfeld; M P Lahaie; A G Wurcel; E Pae; T Roach; M A St John; M Altfeld; F M Marincola; C Moore; S Mallal; M Carrington; T M Allen; J Mullins; D Heckerman; B T Korber; P J R Goulder; B D Walker. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. *Nature Immunol.* 7, pp. 173 - 178. 2006.
Type of production: Scientific paper
- 191** D G Kavanagh; D E Kaufmann; N Frahm; S Sunderji; B S Wagner; S Le Gall; D Boczkowski; M T Zaman; D Stone; E S Rosenberg; C Brander; E Gilboa; B D Walker; N Bhardwaj. Dendritic cells derived from HIV-infected subjects and transfected with mRNA encoding lysosome-targeted antigen drive expansion of antiviral CD4+ and CD8+ T cells with broad specificity and high proliferative capacity. *Blood.* 107(5), pp. 1963 - 1969. 2006.
Type of production: Scientific paper
- 192** A Leslie; D Price; G Tudor-Williams; J Mullins; C Brander; D Douek; P Kiepiela; B D Walker; P J R Goulder. Differential selection pressure exerted by CTL targeting identical epitopes but restricted by distinct alleles within the same HLA supertype. *J Immunol.* 177, pp. 4699 - 4708. 2006.
Type of production: Scientific paper
- 193** J Martinez-Picado; J Pradi; E Fry; K Pfafferoth; A Leslie; S Chetty; C Thobakgale; I Honeybourne; H Crawford; P Matthews; T Pillay; C Rousseau; J Mullins; C Brander; B Walker; D Stuart; P Kiepiela; P Goulder. Fitness cost of escape mutations in p24 in association with control of HIV-1. *J. Virology.* 80(7), pp. 3617 - 3623. 2006.
Type of production: Scientific paper
- 194** F Bihl; N Frahm; L Di Giammarino; J Sidney; M John; K Yusim; T Woodberry; K Sango; H S Hewitt; L Henry; C H Linde; J V Chisholm III; T M Zaman; E Pae; S Mallal; B D Walker; A Sette; B T Korber; D Heckerman; C Brander. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral co-infection on the immunodominance of virus specific CTL responses. *J. Immunology.* 176(7), pp. 4094 - 4101. 2006.
Type of production: Scientific paper
- 195** I Honeyborne; A Rathod; R Buchli; D Ramduth; E Moodley; P Rathnavalu; S Chetty; C Day; C Brander; W Hildebrand; B D Walker; P Kiepiela; P J R Goulder. Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa. *J Immunol.* 176(8), pp. 4699 - 4705. 2006.
Type of production: Scientific paper
- 196** S Adnan; A Balamurugan; A Trocha; M S Bennett; H L Ng; A Ali; C Brander; O O Yang. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. *Blood.* 108(10), pp. 3414 - 3419. 2006.
Type of production: Scientific paper
- 197** R Zuñiga; A Lucchetti; P Galvan; S Sanchez; C Sanchez; A Hernandez; H Sanchez; N Frahm; C H Linde; H S Hewitt; W Hildebrand; M Altfeld; T M Allen; B D Walker; B T Korber; T Leitner; J Sanchez; C Brander. Preferential CTL targeting of HIV Gag-is associated with relative control of HIV infection. *J Virol.* 80(6), pp. 3122 - 3125. 2006.
Type of production: Scientific paper
- 198** S A Islam; S Y Thomas; C Hess; B D Medoff; T K Means; C Brander; C M Lilly; A M Tager; A D Luster. The Leukotriene B4 Lipid Chemoattractant Receptor BLT1 Defines Antigen-primed T-cells in Humans. *Blood.* 107(2), pp. 444 - 453. 2006.
Type of production: Scientific paper
Position of signature: 6



Total no. authors: 9

- 199** T Woodberry; L Henry; M August; F Wang; D T Scadden; C Brander. ?E?? (CD103) identifies tonsil-resident, EBV-specific effector-memory CTL absent from the peripheral blood. *J. Immunol.* 175, pp. 4355 - 4362. 2005.
Type of production: Scientific paper
- 200** T M Allen; X G Yu; E T Kalife; L L Reyor; M Lichterfeld; M John; M Cheng; R L Allgaier; S Mui; N Frahm; G Alter; N V Brown; M N Johnston; E S Rosenberg; S A Mallal; C Brander; B D Walker; M Altfeld. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. *J Virol.* 79(20), pp. 12952 - 12960. 2005.
Type of production: Scientific paper
- 201** D Ramduth; P Chetty; N C Mngquandaniso; N Nene; J D Harlow; I Honeyborne; N Ntumba; S Gappoo; C Henry; P Jeena; M M Addo; M Altfeld; C Brander; C Day; H Coovadia; P Kiepiela; P Goulder; B Walker. Differential Immunogenicity of HIV-1 Clade C Proteins in Eliciting CD8+ and CD4+ Cell Responses. *J Infect Dis.* 192(9), pp. 1588 - 1596. 2005.
Type of production: Scientific paper
- 202** T Woodberry; L Henry; T Suscovich; F Wang; B D Walker; D T Scadden; C Brander. Differential targeting and shifts in immunodominance in EBV- specific CD8 and CD4 T-cell responses from acute to persistent infection. *J. Infectious Diseases.* 192, pp. 1513 - 1524. 2005.
Type of production: Scientific paper
- 203** C Boggiano; R Moya; C Pinilla; F Bihl; C Brander; J Sidney; A Sette; S Blondelle. Discovery and Characterization of Highly Immunogenic and Broadly Recognized Mimics of the HIV-1 CTL Epitope Gag77-85. *European J. Immunol.* 35, pp. 1428 - 1437. 2005.
Type of production: Scientific paper
- 204** N Frahm; S Adams; P Kiepiela; K Sango; C H Linde; M Altfeld; T Allen; B D Walker; F Marincola; C Brander. HLA-B63 (B*1516/B*1517) presents HLA-B57 and -B58 restricted CTL epitopes and is associated with low HIV viral load. *J. Virology.* 79, pp. 10218 - 10225. 2005.
Type of production: Scientific paper
- 205** Y Xu; M Lichterfeld; B Perkins; E Kalife; S Mui; M Cheng; W Kang; G Alter; G Robbins; N Basgoz; R Gandhi; C Brander; B D Walker; M Altfeld. High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses on the single peptide level. *AIDS.* 19, pp. 1449 - 1456. 2005.
Type of production: Scientific paper
- 206** T Woodberry; T Suscovich; L M Henry; J Martin; B D Walker; D T Scadden; C Brander. Impact of Kaposi's sarcoma-associated herpesvirus (KSHV) viral burden and HIV co-infection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. *Journal Inf Dis.* 192, pp. 622 - 629. 2005.
Type of production: Scientific paper
- 207** T M Allen; M Altfeld; S C Geer; E Kalife; K M O'Sullivan; I DeSouza; C Moore; M E Feeney; C Tanzi; R L Eldridge; E L Maier; D E Kaufmann; M P Lahaie; L Reyor; M N Johnston; C Brander; R Draenert; H Jessen; E S Rosenberg; S A Mallal; B D Walker. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. *J Virol.* 79(21), pp. 13239 - 13249. 2005.
Type of production: Scientific paper
- 208** F Bihl; E Loggi; J Chisholm; L Henry; N Frahm; P Andreone; C Brander. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti-CD3 mAb T cell expansion and RecycleSpot. *Journal Transl. Medicine.* 11, pp. 20 - 31. 2005.



Type of production: Scientific paper

- 209** M Altfeld; T M Allen; E T Kalife; N Frahm; M M Addo; B R Mothe; A Rathod; L L Reyor; J Harlow; X G Yu; B Perkins; L K Robinson; J Sidney; G Alter; M Lichterfeld; A Sette; E S Rosenberg; P J Goulder; C Brander; B D Walker. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. *J Virol.* 79(8), pp. 5000 - 5005. 2005.
Type of production: Scientific paper
- 210** A Leslie; D Kavanagh; I Honeyborne; K Pfafferott; C Edwards; T Pillay; L Hilton; C Thobakgale; D Ramduth; R Draenert; S Le Gall; G Luzzi; A Edwards; C Brander; A K Sewell; S Moore; J Mullins; C Moore; S Mallal; N Bhardwaj; K Yusim; R Phillips; P Klenerman; B Korber; P Kiepiela; B Walker; P Goulder. Transmission and accumulation of CTL escape variants drives negative associations between HIV polymorphisms and HLA. *J Exp Med.* 201, pp. 891 - 902. 2005.
Type of production: Scientific paper
- 211** D E Kaufmann; P M Bailey; J Sidney; B Wagner; P J Norris; M N Johnston; L A Cosimi; M M Addo; M Lichterfeld; M Altfeld; N Frahm; C Brander; A Sette; B D Walker; E S Rosenberg. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. *J Virol.* 78(9), pp. 4463 - 4477. 2004.
Type of production: Scientific paper
- 212** N Frahm; B T Korber; C M Adams; J J Szinger; R Draenert; M M Addo; M E Feeney; K Yusim; K Sango; N V Brown; D SenGupta; A Piechocka-Trocha; T Simonis; F M Marincola; A G Wurcel; D R Stone; C J Russell; P Adolf; D Cohen; T Roach; A StJohn; A Khatri; K Davis; J Mullins; P J R Goulder; B D Walker; C Brander. Consistent CTL targeting of immunodominant regions in HIV across multiple ethnicities. *J. Virol.* 78, pp. 2187 - 2000. 2004.
Type of production: Scientific paper
- 213** T J Suscovich; M Paulose-Murphy; J D Harlow; Y Chen; S Y Thomas; T J Mellott; B D Walker; D T Scadden; S Zeichner; C Brander. Defective immune function of Primary Effusion Lymphoma cells is associated with distinct KSHV gene expression profiles. *Leukemia and Lymphoma.* 45, pp. 1223 - 1238. 2004.
Type of production: Scientific paper
- 214** X G Yu; M M Addo; B A Perkins; F Wej; A Rathod; S C Geer; M Parta; D Cohen; D R Stone; C J Russell; G Tanzi; S Mei; A G Wurcel; N Frahm; m Lichterfeld; I Heath; J I Mullins; F Marincola; P J Goulder; C Brander; T Allen; Y Cao; B D Walker; m Altfeld. Differences in the expressed HLA class I alleles effect the differential clustering of HIV type 1-specific T cell responses in infected Chinese and Caucasians. *AIDS Res Hum Retroviruses.* 20(5), pp. 557 - 564. 2004.
Type of production: Scientific paper
- 215** X G Yu; M M Addo; B A Perkins; F Wej; A Rathod; S C Geer; M Parta; D Cohen; D R Stone; C J Russell; G Tanzi; S Mei; A G Wurcel; N Frahm; M Lichterfeld; L Heath; J I Mullins; F Marincola; P J Goulder; C Brander; T Allen; Y Cao; B D Walker; M Altfeld. Differences in the expressed HLA class I alleles impact the differential clustering of HIV-1-specific T cell responses in infected Chinese and Caucasians. *AIDS Research and Human.* 20, pp. 557 - 565. 2004.
Type of production: Scientific paper
- 216** P Kiepiela; A J Leslie; I Honeyborne; D Ramduth; C Thobakgale; S Chetty; P Rathnavalu; C Moore; K J Pfafferott; L Hilton; P Zimbwa; S Moore; T Allen; C Brander; M M Addo; M Altfeld; I James; S Mallal; M Bunce; L D Barber; J Szinger; P Klenerman; J Mullins; B Korber; H M Coovadia; B D Walker; P J Goulder. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. *Nature.* 432, pp. 769 - 775. 2004.
Type of production: Scientific paper



- 217** P J Norris; H F Moffett; C Brander; T M Allen; K M O'Sullivan; L A Cosimi; D E Kaufmann; B D Walker; E S Rosenberg. Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+T cells. *AIDS Res Hum Retroviruses*. 2004.
Type of production: Scientific paper
- 218** A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J Goulder. HIV evolution: CTL escape mutation and reversion after transmission. *Nat Med*. 2004.
Type of production: Scientific paper
- 219** D SenGupta; P J Norris; T J Suscovich; M Hassan-Zahraee; H F Hassan-Zahraee; A Trocha; R Draenert; P J Goulder; R J Binder; D L Levey; B D Walker; P K Srivastava; C Brander. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. *J Immunol*. 173(3), pp. 1987 - 1993. 2004.
Type of production: Scientific paper
- 220** C Hess; T K Means; P Autissier; T Woodberry; M Altfeld; M Addo; N Frahm; C Brander; B D Walker; A D Luster. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. *Blood*. 104(12), pp. 3463 - 3471. 2004.
Type of production: Scientific paper
- 221** R Draenert; S LeGall; K J Pfafferott; A J Leslie; P Chetty; C Brander; E C Holmes; S C Chang; M E Feeney; M M Addo; L Ruiz; D Ramduth; P Jeena; M Altfeld; S Thomas; Y Tang; C L Verrill; C Dixon; J G Prado; P Kiepiela; J Martinez-Picado; B D Walker; P J Goulder. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. *J Exp Med*. 199(7), pp. 905 - 915. 2004.
Type of production: Scientific paper
- 222** R Draenert; C Brander; X G Yu; M Altfeld; C L Verrill; M E Feeney; B D Walker; P J Goulder. Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels. *AIDS*. 18(6), pp. 871 - 876. 2004.
Type of production: Scientific paper
- 223** T M Allen; M Altfeld; X G Yu; K M O'Sullivan; M Lichterfeld; S LeGall; M John; B R Mothe; P K Lee; E T Kalife; D E Cohen; K A Freedberg; D A Strick; M N Johnston; A Sette; E S Rosenberg; S A Mallal; P J Goulder; C Brander; B D Walker. Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. *J Virol*. 78(13), pp. 7069 - 7078. 2004.
Type of production: Scientific paper
- 224** R Draenert; M Altfeld; C Brander; N Basgoz; C Corcoran; A G Wurcel; D R Stone; S A Kalams; A Trocha; M M Addo; P J R Goulder; B D Walker. Broadly directed CD4 and CD8 T cell responses to HIV-1 Nef but lack of correlation with control of viremia. *J Immunol Methods*. 275, pp. 19 - 29. 2003.
Type of production: Scientific paper
- 225** M Addo; X G Yu; A Rathod; D Cohen; R L Eldridge; D Strick; M N Johnston; C Corcoran; A G Wurcel; C A Fitzpatrick; M E Feeney; W R Rodriguez; N Basgoz; R Draenert; D R Stone; C Brander; P J R Goulder; E S Rosenberg; M Altfeld; B D Walker. Comprehensive epitope analysis of HIV-1-specific T cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. *J Virol*. 77(3), pp. 2081 - 2092. 2003.
Type of production: Scientific paper
- 226** O O Yang; P T Sarkis; A Ali; J D Harlow; C Brander; S A Kalams; B D Walker. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. *J Exp Med*. 197, pp. 1365 - 1375. 2003.
Type of production: Scientific paper



- 227** M Altfeld; MM Addo; R Shankarappa; P K Lee; T M Allen; X G Yu; A Rathod; J Harlow; K O'Sullivan; M N Johnston; P J Goulder; J I Mullins; E S Rosenberg; C Brander; B Korber; B D Walker. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. *J Virol.* 77(13), pp. 7330 - 7340. 2003.
Type of production: Scientific paper
- 228** M Altfeld; T Allen; X Yu; M N Johnston; D Agrawal; B Korber; D C Montefiori; D H O'Connor; B Davis; P K Lee; J Harlow; C Brander; E S Rosenberg; B D Walker. . HIV-1 superinfection despite broadly directed CD8+ T cell responses containing replication of the primary virus. *Nature.* 420, pp. 434 - 439. 2002.
Type of production: Scientific paper
- 229** C Brander; N Raje; P G O'Connor; F Davies; J Davis; D Chauhan; T Hideshima; J Martin; D Osmond; D Kedes; B D Walker; D T Scadden; K C Anderson. Absence of biologically significant Kaposi's sarcoma-associated herpesvirus (KSHV) gene products and virus specific cellular immune responses in multiple myeloma. *Blood.* 100(2), pp. 698 - 700. 2002.
Type of production: Scientific paper
- 230** G B Cohen; S A Islam; M S Noble; C Lau; C Brander; M Altfeld; E S Rosenberg; J E Schmitz; T O Cameron; S A Kalams. Clonotype Tracking on TCR Repertoires During Chronic Virus Infections. *Virology.* 304(2), pp. 474 - 484. 2002.
Type of production: Scientific paper
- 231** B Lotti; T Wendland; T Nguyen; E Rosenberg; W Pichler. Cytotoxic HIV-1 p55 gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. *J Clin Immunol.* 22, pp. 253 - 262. 2002.
Type of production: Scientific paper
- 232** X G Yu; H Shang; M M Addo; R L Eldridge; M N Phillips; M E Feeney; D Strick; C Brander; P J Goulder; E S Rosenberg; B D Walker; M Altfeld. Important contribution of p15 gag-specific responses to the total gag-specific CTL responses. *AIDS.* 16(3), pp. 321 - 328. 2002.
Type of production: Scientific paper
- 233** M Altfeld; E Rosenberg; R Eldridge; S Poon; G Robbins; S Kalams; C Brander; P Goulder; B Walker. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. *J Exp Med.* 193, pp. 169 - 180. 2001.
Type of production: Scientific paper
- 234** A D Kelleher; C Long; E C Holmes; R Allen; J Wilson; C Conlon; C Workman; S Shuanak; K Wulfestieg; P Goulder; C Brander; G Ogg; J Sullivan; W Dyer; I Jones; A McMichael; S Rowland-Jones; R Phillips. Clustered mutations in HIV-1 Gag are consistently required for escape from HLA-B27 restricted CTL responses. *J Exp Med.* 193, pp. 375 - 386. 2001.
Type of production: Scientific paper
- 235** C Brander; P O'Connor; T Suscovich; N Jones; Y Lee; D Kedes; D Ganem; J Martin; D Osmond; S Southwood; A Sette; B D Walker; D T Scadden. Definition of an optimal cytotoxic T lymphocytes (CTL) epitope in the latently expressed Kaposi's sarcoma associated herpes virus (KSHV) kaposin protein. *J Inf Dis.* 184, pp. 119 - 126. 2001.
Type of production: Scientific paper
- 236** P J Goulder; C Brander; Y Tang; C Tremblay; R Colbert; M Addo; E Rosenberg; T Nguyen; A Trocha; S He; M Bunce; R Funkhauser; S Pelton; S Burchett; K McIntosh; B Korber; B D Walker. Evolution and transmission of stable CTL escape mutations in HIV infection. *Nature.* 412, pp. 334 - 338. 2001.
Type of production: Scientific paper



- 237** M A Altfeld; B Livingston; N Reshamwala; P T Nguyen; M M Addo; A Shea; M Newman; J Fikes; J Sidney; P Wentworth; R Chesnut; R L Eldridge; E S Rosenberg; G K Robbins; C Brander; P E Sax; S Boswell; T Flynn; S Buchbinder; P J Goulder; B D Walker; A Sette; S A Kalams. Identification of novel HLA-A2 restricted HIV-1-specific CTL epitopes predicted by the HLA-A2 supertype peptide-binding motif. *J Virol.* 75, pp. 1301 - 1311. 2001.
Type of production: Scientific paper
- 238** C Brander; U Matter-Reissmann; N G Jones; B D Walker; D H Sachs; J Seebach. Inhibition of human NK cell-mediated cytotoxicity by exposure to ammonium chloride. *J. Immunol. Methods.* 252, pp. 1 - 14. 2001.
Type of production: Scientific paper
- 239** P J Goulder; C Rasquier; E C Holmes; B Liang; Y Tang; J Izopet; K Saune; E S Rosenberg; S K Burchett; K McIntosh; M Barnardo; M Bunce; B D Walker; C Brander; M Phillips. Mother-to-child transmission of HIV infection and CTL escape through HLA-A2 SLYNTVATL epitope sequence variation. *Immunol. Lett.* 79, pp. 109 - 116. 2001.
Type of production: Scientific paper
- 240** P J Norris; M Sumaroka; C Brander; H F Moffett; S L Boswell; T Nguyen; Y Sykulev; B D Walker; E S Rosenberg. Multiple effector functions mediated by HIV-1 specific CD4+ T cell clones. *J Virol.* 20, pp. 9771 - 9779. 2001.
Type of production: Scientific paper
- 241** P Goulder; M Altfeld; E Rosenberg; T Nguyen; Y Tang; R Eldridge; M Addo; S He; J Mukerjee; M Phillips; G Ogg; S Kalams; R Sekaly; B Walker; C Brander. Substantial differences in specificity of HIV specific cytotoxic T cells in acute and chronic HIV infection. *J Exp Med.* 193, pp. 181 - 194. 2001.
Type of production: Scientific paper
- 242** M Addo; M Altfeld; E S Rosenberg; R L Eldridge; M N Philips; K Habeeb; A Khatri; C Brander; G K Robbins; G P Mazzara; P J Goulder; B D Walker; the HIV Controller Study Collaboration. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. *Proc Natl Acad Sci USA.* 98, pp. 1781 - 1786. 2001.
Type of production: Scientific paper
- 243** M Altfeld; M A Addo; R Eldridge; X Yu; S Thomas; A Khatri; D Strick; M N Phillips; G Cohen; S Islam; S Kalams; C Brander; P J R Goulder; E S Rosenberg; B D Walker. Vpr is preferentially targeted by CTL during HIV-1 infection. *J Immunol.* 167, pp. 2743 - 2752. 2001.
Type of production: Scientific paper
- 244** P J Goulder; C Brander; K Annamalai; N Mngqundaniso; U Govender; Y Tang; S He; K E Hartman; C A O'Callaghan; G S Ogg; M A Altfeld; E S Rosenberg; H Cao; S A Kalams; M Hammond; M Bunce; S I Pelton; S A Burchett; K McIntosh; H M Coovadia; B D Walker. Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children. *J Virol.* 74, pp. 5679 - 5690. 2000.
Type of production: Scientific paper
- 245** M C Poznansky; R H Evans; R B Foxall; Y T Olszak; A H Piascik; K E Hartman; C Brander; T Meyer; M Pykett; S Kalams; N Rosenzweig; D T Scadden. Efficient human T-cell generation using a thymic organoid on a biocompatible, inorganic grid. *Nature Biotechnology.* 74, pp. 5679 - 5690. 2000.
Type of production: Scientific paper
- 246** P J R Goulder; T Yuanhua; C Brander; M R Betts; A Trocha; S He; E Rosenberg; G Ogg; C A O'Callaghan; S Kalams; R E McKinney; K Mayer; R Koup; S I Pelton; S K Burchett; K McIntoch; B D Walker. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. *J Exp Med.* 192, pp. 1819 - 1832. 2000.
Type of production: Scientific paper



- 247** C Brander; T Suscovich; Y Lee; T Nguyen; P O'Connor; J Seebach; N G Jones; M van Gorder; B D Walker; D T Scadden. Impaired CTL recognition of cells latently infected with Kaposi's Sarcoma associated Herpes Virus (KSHV/HHV8). *J. Immunol.* 165, pp. 2077 - 2083. 2000.
Type of production: Scientific paper
- 248** C Brander; O O Yang; N G Jones; P J R Goulder; S A Kalams; D Colbert; S Buchbinder; S Wolinsky; B D Walker. Efficient processing of the immunodominant, HLA-A*0201 restricted HIV-1 CTL epitope despite multiple variations in the epitope flanking sequences. *J. Virol.* 73, pp. 10191 - 10198. 1999.
Type of production: Scientific paper
- 249** C Brander; P J R Goulder; K Luzuriaga; O O Yang; K E Hartman; N G Jones; B D Walker; S A Kalams. Persistent HIV-1 specific CTL clonal expansion despite high viral burden post in-utero HIV-1 infection. *J. Immunol.* 162, pp. 4796 - 4800. 1999.
Type of production: Scientific paper
- 250** C Brander; K E Hartman; A K Trocha; N G Jones; S He; P Wentworth; G Hermanson; S P Buchbinder; R P Johnson; B D Walker; S A Kalams. Lack of strong immune selection pressure by the immunodominant HLA-A*0201 restricted CTL response in chronic HIV infection. *J Clin Invest.* 101, pp. 2559 - 2566. 1998.
Type of production: Scientific paper
- 251** M P Zanni; D Mauri-Hellweg; C Brander; T Wendland; B Schnyder; E Frei; S von Greyerz; A Bircher; W J Pichler. Characterization of lidocaine specific T cells. *J Immunol.* 158, pp. 1139 - 1148. 1997.
Type of production: Scientific paper
- 252** J Walter; C Brander; M Mammen; D N Garboczi; S Kalams; G S Whitesides; B D Walker; H Eisen. Stimulation of human cytotoxic T cells with HIV-1 derived peptides presented by recombinant HLA-A2 peptide complexes. *Immunol.* 9, pp. 451 - 459. 1997.
Type of production: Scientific paper
- 253** D Mauri-Hellweg; M Zanni; E Frei; F Bettens; C Brander; D Mauri; E Padovan; H Weltzien; W J Pichler. Crossreactivity of T cell lines and clones to b-lactam antibiotics. *J Immunol.* 157, pp. 1071 - 1079. 1996.
Type of production: Scientific paper
- 254** C Brander; G Corradin; T Hasler; W J Pichler. Peptide Immunization in Humans: A combined CD8+/CD4+ T cell targeted vaccine restimulates the memory CD4 T-cell response but fails to induce cytotoxic T-lymphocytes (CTL). *Clin Exp Immunol.* 105, pp. 18 - 25. 1996.
Type of production: Scientific paper
- 255** M P Zanni; S von Greyerz; B Schnyder; D Mauri-Hellweg; C Brander; C Kalbermatten. Various reactions of T lymphocytes in patients showing adverse reactions to drugs. *Allerg Clin Immunol Int.* 8, pp. 126 - 130. 1996.
Type of production: Scientific paper
- 256** D Mauri-Hellweg; F Bettens; D Mauri; C Brander; T Hunziker; W J Pichler. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. *J Immunol.* 155, pp. 462 - 472. 1995.
Type of production: Scientific paper
- 257** C Brander; D Mauri-Hellweg; F Bettens; H Rolli; M Goldman; W J Pichler. Heterogeneous T cell responses to b-lactam-modified self structures are observed in penicillin allergic individuals. *J Immunol.* 155, pp. 2670 - 2678. 1995.
Type of production: Scientific paper



Total no. authors: 9

- 270** Carla Usai; Lourdes Mateu; Christian Brander; Julia Vergara-Alert; Joaquim Segalés. Animal models to study the neurological manifestations of the post-COVID-19 condition. *Lab Animal*. 52 - 9, pp. 202 - 210. Nature, 2023.
Type of production: Review **Format:** Journal
Position of signature: 3
Total no. authors: 5 **Corresponding author:** No
- 271** B Mothe; C Brander. Considerations for successful therapeutic immunization in HIV cure. *Curr Opin HIV AIDS*. 16 - 5, pp. 257 - 261. 2021.
DOI: 10.1097/COH.0000000000000696
Type of production: Review
Position of signature: 2
Total no. authors: 2
- 272** J Prado; J Carrillo Molina; J Blanco-Heredia; C Brander. Immune correlates of HIV control. *Curr Med Chem*. 18(26), pp. 3963 - 3970. 2011.
Type of production: Scientific-technical report
- 273** C Brander; F M Marincola. AAAS joins the Translational Medicine family. *J Transl Med*. 7, pp. 32. 07/05/2009.
Type of production: Scientific-technical report
- 274** A Llano; A Williams; A Olvera; S Silva-Arrieta; C Brander. Best-Characterized HIV-1 CTL Epitopes: The 2013 Update HIV Molecular Immunology Database. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA. Part IV, pp. 3-24. 2009.
Type of production: Scientific-technical report **Format:** Scientific and technical document or report
- 275** A Llano; N Frahm; C Brander. How to Optimally Define Optimal Cytotoxic T Lymphocyte Epitopes in HIV Infection?. HIV Molecular Immunology Database. Part IV, pp. 3 - 24. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2009.
Type of production: Scientific-technical report
- 276** B Mothe; J Ibarrondo; A Llano; C Brander. Virological, immune and host genetics markers in the control of HIV infection. *Dis Markers*. 27(3), pp. 105 - 120. 2009.
Type of production: Scientific-technical report
- 277** F Bihl; D Castelli; F Marincola; R Dodd; C Brander. Transfusion-transmitted infections. *J Transl Med*. 5, pp. 25. 06/06/2007.
Type of production: Scientific-technical report
- 278** C Brander; S Self; B Korber. Capturing viral for in vitro test reagents and HIV vaccine immunogen. *Curr Opin HIV AIDS*. 2(3), pp. 183 - 188. 05/2007.
Type of production: Scientific-technical report
- 279** N Frahm; C Brander. Viral diversity and HIV immune escape. *Curr Infect Dis Rep*. 9(2), pp. 161 - 1616. 03/2007.
Type of production: Scientific-technical report
- 280** C Brander; S Ferrone; F M Marincola. Rewarding patient-directed research: Excellence in Translational Medicine Award. *J Transl Med*. 4(1), pp. 19. 03/05/2006.
Type of production: Scientific-technical report



- 281** C Brander; N Frahm; B D Walker. Host immunity and viral diversity in HIV vaccine design. *Curr Opin Immunol.* (4), pp. 430 - 437. 2006.
Type of production: Scientific-technical report
- 282** D L Levey; C Brander; P K Srivastava. Heat shock protein-peptide complexes for generation of therapeutic immunity to HIV. *J HIV Ther.* 10(3), pp. 56 - 59. 09/2005.
Type of production: Scientific-technical report
- 283** R F Speck; C Brander; T M Kündig. HIV-1 vaccination - is there hope?. *Therapeutische Umschau.* 62, pp. 695 - 702. 2005.
Type of production: Scientific-technical report
- 284** N Frahm; N Linde; C Brander. Identification of HIV-derived, HLA class I restricted CTL epitopes: insights into TCR diversity, CTL escape and viral fitness. *HIV Molecular Immunology Database. Part IV*, pp. 1 - 21. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2005.
Type of production: Scientific-technical report
- 285** HIV and HLA: Implications for vaccine design. *American Society of Histocompatibility and Immunogenetics. Quartely Newsletter.* pp. 57 - 59. 2004.
Type of production: Scientific-technical report
- 286** S P Mankoff; C Brander; S Ferrone; F M Marincola. Lost in Translation: Obstacles to Translational Medicine. *J Transl Med.* 2(1), pp. 14. 2004.
Type of production: Scientific-technical report
- 287** N Frahm; C Brander. Optimal CTL epitope identification in clade B and non-clade B infection. *HIV Molecular Immunology Database. Part IV*, pp. 3 - 20. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2004.
Type of production: Scientific-technical report
- 288** C Brander; B D Walker. Gradual adaptation of HIV to human host populations: good or bad news?. *Nat Med.* 9(11), pp. 1359 - 1362. 2003.
Type of production: Scientific-technical report
- 289** N Frahm; P Goulder; C Brander. Total Assessment of HIV-Specific CTL Responses: Epitope Clustering, Processing Preferences, and the Impact of HIV Sequence Heterogeneity. *HIV Molecular Immunology Database. Part IV*, pp. 1 - 20. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2003.
Type of production: Scientific-technical report
- 290** N Frahm; P Goulder; C Brander. Broad HIV-1 specific CTL Responses Reveal Extensive HLA Class I Binding Promiscuity of HIV-Derived, Optimally Defined CTL epitopes. *HIV Molecular Immunology Database. Part IV*, pp. 1 - 19. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2002.
Type of production: Scientific-technical report
- 291** C Brander; Y Rivière. Early and late cytotoxic T lymphocyte responses in HIV infection. *AIDS.* 2002.
Type of production: Scientific-technical report
- 292** C Brander; B D Walker. Modulation of host immune responses by clinically relevant human DNA and RNA viruses. *Curr. Opin. Microbiol.* 4, pp. 379 - 386. 2000.
Type of production: Scientific-technical report



- 293** C Calef; R Thakallapally; D Lang; C Brander; P Goulder; O Yang; B Korber. PeptGen: Designing Peptides for Immunological Studies and Application to HIV Consensus Sequences. Human Retroviruses and AIDS 2000: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2000.
Type of production: Scientific-technical report
- 294** C Brander; P Goulder. The evolving field of HIV CTL epitope mapping: New approaches for the identification of novel epitopes. HIV Molecular Immunology Database. Part IV, pp. 1 - 18. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 2000.
Type of production: Scientific-technical report
- 295** C Brander; P J R Goulder. Recent advances in HIV-1 CTL epitope characterization. HIV Molecular Immunology Database. Part IV, pp. 1 - 17. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 1999.
Type of production: Scientific-technical report
- 296** C Brander; B D Walker. T lymphocyte responses in HIV-1 infection: Implications for vaccine development. Curr Opin Immunol. 11, pp. 451 - 459. 1999.
Type of production: Scientific-technical report
- 297** C Brander; B D Walker. The HLA class I restricted CTL response in HIV-1 infection: Systematic identification of optimal epitopes. HIV Molecular Immunology Database. Part IV, pp. 1 - 11. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 1996.
Type of production: Scientific-technical report
- 298** C Brander; B D Walker. The HLA-class I restricted CTL response in HIV-1 infection: Identification of optimal epitopes. HIV Molecular Immunology Database. Part IV, pp. 1 - 9. Los Alamos National Laboratory: Theoretical Biology and Biophysics, Los Alamos, NM, USA, 1995.
Type of production: Scientific-technical report

Works submitted to national or international conferences

- 1** **Title of the work:** Therapies and vaccines against the virus - (Therapeutic) HPV Vaccine
Name of the conference: The BCN HPV Course
Type of event: Conference
Type of participation: Participatory - Plenary session
Reasons for participation: Upon invitation
Corresponding author: Yes
City of event: Barcelona, Catalonia, Spain
Date of event: 04/10/2023
End date: 04/10/2023
Organising entity: FLS
- 2** **Title of the work:** T-cell vaccines as a component of an effective HIV cure
Name of the conference: NIAID Workshop on T & B Cell Synergy for HIV Vaccines
Type of event: Workshop
Type of participation: Participatory - invited/keynote
Reasons for participation: Upon invitation talk
City of event: Washington, United States of America
Date of event: 08/08/2023
End date: 09/08/2023

Organising entity: Instituto de Salud Carlos III

- 3** **Title of the work:** T-cell responses induced by HTI vaccines and vesatolimod correlate with improved control of HIV rebound
Name of the conference: 12th IAS Conference on HIV Science
Corresponding author: Yes
City of event: Brisbane, Australia
Date of event: 24/07/2023
End date: 26/07/2023
Organising entity: Instituto de Agricultura Sostenible
Beatriz Mothe; Lucia Bailon; Adrian Curran; Juan Lopez; Luis Cadinanos; Michelle Frankot; Elena Vendrame; Ian MvGowan; Christian Brander; Jose Ramon Arribas.
- 4** **Title of the work:** Immune-based strategies for HIV Cure
Name of the conference: Cell Symposium: Viruses in Health and Disease 2023
Type of event: Conference
Type of participation: Participatory - Plenary session
Reasons for participation: Upon invitation
Corresponding author: Yes
City of event: Sitges, Catalonia, Spain
Date of event: 20/03/2023
End date: 20/03/2023
Organising entity: Cell Press
- 5** **Title of the work:** A Placebo-Controlled Randomized Trial of the HTI Immunogen Vaccine and Vesatolimod
Name of the conference: CROI 2023
Type of event: Conference
Type of participation: Participatory - poster
Corresponding author: Yes
City of event: Seattle, United States of America
Date of event: 19/02/2023
End date: 23/02/2023
Organising entity: CROI
- 6** **Title of the work:** Repeated intramuscular administration of the HIV-1 therapeutic prime-boost vaccine combination DNA.HTI and MVA.HTI
Name of the conference: EuroTox 2017
City of event: Bratislava, Slovakia
Date of event: 10/09/2017
End date: 13/09/2017
Organising entity: European Societies of Toxicology
- 7** **Title of the work:** O-glcnac glycosylation of HIV synthetic epitopes reduces cytotoxic T cell recognition
Name of the conference: EuroCarb 2017
City of event: Barcelona, Catalonia, Spain
Date of event: 02/07/2017
End date: 06/07/2017
Organising entity: European Carbohydrate Organisation
G Arsequell; G Valencia; C Brander; A Olvera.



- 8** **Title of the work:** DNA methylation profiles identify epigenetically regulated host factors associated with immune control of HIV infection
Name of the conference: Hijacking host signalling and epigenetic mimicry during infections
City of event: Paris, France
Date of event: 13/06/2017
End date: 16/06/2017
Organising entity: Institute Pasteur
- 9** **Title of the work:** Challenges and opportunities conducting research with US NIH grant funding
Name of the conference: NIH Post Award Grants Policy and Management Training
Corresponding author: Yes
City of event: Barcelona, Catalonia, Spain
Date of event: 06/06/2017
End date: 06/06/2017
Organising entity: National Institutes of Health
- 10** **Title of the work:** Inflammatory and Regulatory Cytokine Profiles in HIV+-to-HIV+ Renal Transplant Recipients
Name of the conference: 31st European Immunogenetics and Histocompatibility Congress
City of event: Heidelberg, Germany
Date of event: 30/05/2017
End date: 02/06/2017
Organising entity: German Society for Immunogenetics
- 11** **Title of the work:** Early cART of HIV-1 infected subjects preserves antiviral function of CD8+ T cells
Name of the conference: CROI 2017
City of event: Seattle, United States of America
Date of event: 13/02/2017
End date: 16/02/2017
Organising entity: CROI Foundation
- 12** **Title of the work:** GENOME-WIDE METHYLATION IS ASSOCIATED WITH HIV-1 INFECTION AND DISEASE PROGRESSION
Name of the conference: CROI 2017
City of event: Seattle, United States of America
Date of event: 13/02/2017
End date: 16/02/2017
Organising entity: CROI Foundation
- 13** **Title of the work:** Risk factors of acute organ rejection after liver transplantation in HIV+/HCV+ patients
Name of the conference: CROI 2017
City of event: Seattle, United States of America
Date of event: 13/02/2017
End date: 16/02/2017
Organising entity: CROI Foundation
- 14** **Title of the work:** Viral control induced by HIVCconsv vaccines and Romidepsin in early treated individuals
Name of the conference: CROI 2017
City of event: Seattle, United States of America
Date of event: 13/02/2017
Organising entity: CROI Foundation



- 15** **Title of the work:** Mechanisms of abrupt HIV disease progression in a cohort of previous elite and viremic HIV controllers
Name of the conference: HIV Research for Prevention HIVR4P
City of event: Chicago, United States of America
Date of event: 19/10/2016
Organising entity: Global AIDS Vaccine Enterprise **Type of entity:** Foundation
City organizing entity: New York, United States of America
C Brander.
- 16** **Title of the work:** Analysis of the immune system during HIV infection
Name of the conference: World Vaccine Congress Europe
City of event: Barcelona, Catalonia, Spain
Date of event: 11/10/2016
- 17** **Title of the work:** Influence of genetic, virologic and immunologic factors on outcomes of HCV/HIV OLT
Date of event: 28/09/2016
Organising entity: FIPSE **Type of entity:** Foundation
- 18** **Title of the work:** Identification of biomarkers of HIV control to inform HIV vaccine development
City of event: Badalona, Catalonia, Spain
Date of event: 16/07/2016
Organising entity: Hospital Universitari Germans Trias i Pujol
City organizing entity: Badalona, Catalonia, Spain
- 19** **Title of the work:** Immune studies in HIV+ to HIV+ organ transplantation
City of event: Stellenbosch - Sudáfrica,
Date of event: 21/05/2016
Organising entity: University of Capetown **Type of entity:** University
City organizing entity: Stellenbosch - Sudáfrica,
- 20** **Title of the work:** Considerations for the development of preventive and therapeutic HIV vaccines
City of event: Vic, Catalonia, Spain
Date of event: 17/05/2016
Organising entity: Universitat de Vic **Type of entity:** University
City organizing entity: Vic, Catalonia, Spain
- 21** **Title of the work:** Emerging data from the CUTHIVAC03 trial in Lima, Peru
Name of the conference: CUTHIVAC Meeting
City of event: Florenze, Italy
Date of event: 30/11/2015
Organising entity: INSERM **Type of entity:** Public Research Body
City organizing entity: Paris, France
- 22** **Title of the work:** Epigenetic control of host plasma markers associated with HIV control
Name of the conference: International Workshop on Biomedical Big Data
City of event: Bellaterra, Catalonia, Spain
Date of event: 27/11/2015
Organising entity: BiostatNet **Type of entity:** Associations and Groups



- 23** **Title of the work:** Prospects for HIV Cure and Post Treatment Remission
Name of the conference: 15 European AIDS Conference
City of event: Barcelona, Catalonia, Spain
Date of event: 23/10/2015
Organising entity: European AIDS Clinical Society **Type of entity:** Associations and Groups
- 24** **Title of the work:** Epigenetic control of plasma "communicom" factors associated with HIV control
Name of the conference: World Immune Regulation Meeting
City of event: Davos, Switzerland
Date of event: 20/03/2015
Organising entity: Swiss Institute of Allergy and Asthma Research **Type of entity:** University Research Institute
- 25** **Title of the work:** Does allo-HLA host genetics impact HCV viral evolution post liver transplantation ?
Name of the conference: World Immune Regulation Meeting
City of event: Davos, Switzerland
Date of event: 19/03/2015
Organising entity: Swiss Institute of Allergy and Asthma Research **Type of entity:** University Research Institute
- 26** **Title of the work:** Impact of donor host genetics on HCV viral evolution after liver transplantation
City of event: Boston, United States of America
Date of event: 09/11/2014
Organising entity: American Association for the Study of Liver Disease **Type of entity:** Associations and Groups
- 27** **Title of the work:** What can biostatistics do for health research
City of event: Barcelona, Catalonia, Spain
Date of event: 11/2014
Organising entity: Catalan Statistics Society **Type of entity:** Associations and Groups
- 28** **Title of the work:** HIV vaccine design
City of event: Hamburg, Germany
Date of event: 05/06/2014
Organising entity: Heinrich Pette Institute
- 29** **Title of the work:** Roadblocks in HIV vaccine design
City of event: Ginebra, Switzerland
Date of event: 23/05/2014
Organising entity: Geneva University
- 30** **Title of the work:** Therapeutic Vaccines and HIV Eradication
Name of the conference: Hot topics in HIV: Vaccines, Immune Recovery and Eradication
City of event: Barcelona, Catalonia, Spain
Date of event: 10/10/2013
Organising entity: Fight Against AIDS Foundation **Type of entity:** Foundation
- 31** **Title of the work:** Immunogen design in HIVACAT
Name of the conference: AIDS Vaccine Meeting
City of event: Barcelona, Catalonia, Spain
Date of event: 09/10/2013



Organising entity: Global AIDS Vaccine Enterprise **Type of entity:** Foundation

- 32 Title of the work:** Alternative approaches to HIV immunogen design
Name of the conference: Jenner Seminar Series
City of event: Oxford, United Kingdom
Date of event: 11/07/2013
Organising entity: Churchill Hospital, University of Oxford **Type of entity:** University
- 33 Title of the work:** T cell immunogens in preventive and therapeutic HIV vaccine development
Name of the conference: 6th South African AIDS Conference
City of event: Durban, South African Republic
Date of event: 20/06/2013
- 34 Title of the work:** Strategies for preventive and therapeutic HIV vaccines
Name of the conference: Seminar Series
City of event: Barcelona, Catalonia, Spain
Date of event: 03/04/2013
Organising entity: Hospital Universitari Germans Trias i Pujol de Badalona **Type of entity:** Healthcare Institutions
- 35 Title of the work:** Prolonged Preservation of HIV--specific Cellular Immunity in Recently HIV+ Individuals Receiving Maraviroc Intensified HAART (Poster abstract: 341)
Name of the conference: CROI 2013
City of event: Atlanta, United States of America
Date of event: 03/03/2013
End date: 06/03/2013
Organising entity: CROI
A Kawana--Tachikawa; J Llibre; I Bravo; R Escrig; B Mothe; J Miró; JM Gatell; A Iwamoto; B Clotet; C Brander.
- 36 Title of the work:** European Contributions to the Search for an HIV Vaccine: HIVACAT Research and Funding
Name of the conference: AVAC AIDS Vaccines Webinar
City of event: Webinar,
Date of event: 29/01/2013
Organising entity: AVAC
- 37 Title of the work:** Towards HIV control
Name of the conference: 26th Annual Meeting of the Japanese Society for AIDS Research
City of event: Tokyo, Japan
Date of event: 25/11/2012
End date: 25/11/2012
Organising entity: Japanese Society for AIDS Research **Type of entity:** Associations and Groups
City organizing entity: Tokyo, Japan
C Brander.
- 38 Title of the work:** Poster: A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control of HIV is immunogenic in mice and is able to break CTL immunodominance
Name of the conference: AIDS Vaccine 2012

City of event: Boston, United States of America
Date of event: 09/09/2012
End date: 12/09/2012
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation

39 **Title of the work:** Poster: HIV-1 p24 derived epitopes modulate KIR2DL2-binding to HLA-Cw03
Name of the conference: AIDS Vaccine 2012
City of event: Boston, United States of America
Date of event: 09/09/2012
End date: 12/09/2012
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation

40 **Title of the work:** Poster: Modulation of antibody secreting cells and neutralizing Ab activity in HIV infected individuals undergoing structured treatment interruptions
Name of the conference: AIDS Vaccine 2012
City of event: Boston, United States of America
Date of event: 09/09/2012
End date: 12/09/2012
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation

41 **Title of the work:** Estado actual de las vacunas frente al VIH
Name of the conference: 15ª Jornada Tratamiento Antirretroviral en Pediatría
City of event: Barcelona, Catalonia, Spain
Date of event: 26/11/2011
End date: 26/11/2011
Organising entity: Fundación Lucía
C Brander.

42 **Title of the work:** Strategies for preventive and therapeutic HIV vaccines
Name of the conference: 6th Symposium of the Spanish Vaccine Association
City of event: Santiago de Compostela, Galicia, Spain
Date of event: 25/11/2011
End date: 25/11/2011
Organising entity: Spanish Vaccine Association
C Brander.

43 **Title of the work:** Check-ear cohort: a community and researchers collaboration for STIs screening in HIV negative MSM"
Name of the conference: CWTSE Femp 2011
City of event: Stockholm, Sweden
Date of event: 10/11/2011
End date: 10/11/2011
Organising entity: FEMP **Type of entity:** Associations and Groups
C Brander.

44 **Title of the work:** Poster:Protective HLA class I alleles in HCV infection: Immune control linked to clustered CD8 escape mutations in NS5b by large-scale sequence analysis
Name of the conference: American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011)
City of event: San Francisco, United States of America
Date of event: 05/11/2011



End date: 05/11/2011

Organising entity: American Association for the Study of Liver Diseases

Type of entity: Associations and Groups

City organizing entity: San Francisco, United States of America

- 45** **Title of the work:** Poster: Perceived stress is a strong predictor of elevated levels of IL-6 in HIV-infected, cART-treated individuals
Name of the conference: 2nd International Workshop on HIV & Aging
City of event: Baltimore, United States of America
Date of event: 28/10/2011
End date: 28/10/2011
Organising entity: Virology Education **Type of entity:** Business
- 46** **Title of the work:** Vaccines and immune recovery. Hot Topics in HIV: Vaccines, Immune Recovery and Eradication
Name of the conference: Seminar Series FLS
City of event: Barcelona, Spain
Date of event: 18/10/2011
End date: 18/10/2011
Organising entity: Fundació Lluita contra la Sida **Type of entity:** Foundation
- 47** **Title of the work:** Progress and hurdles in the development of therapeutic and preventive HIV vaccines
Name of the conference: 7th European Congress on Tropical Medicine & International Health
City of event: Barcelona, Catalonia, Spain
Date of event: 03/10/2011
End date: 03/10/2011
Organising entity: Federation of European Societies for Tropical Medicine and International Health
C Brander.
- 48** **Title of the work:** Conserved Elements (CE) Vaccine
Name of the conference: AIDS Vaccine 2011
City of event: Bangkok, Thailand
Date of event: 12/09/2011
End date: 16/09/2011
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation
C Brander.
- 49** **Title of the work:** Poster: DTH reaction to defined CTL epitopes
Name of the conference: AIDS Vaccine 2011
City of event: Bangkok, Thailand
Date of event: 12/09/2011
End date: 16/09/2011
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation
- 50** **Title of the work:** Poster: Factors influencing recruitment, retention and seroconversion rates in MSM at high risk for HIV infection in Lima and Barcelona
Name of the conference: AIDS Vaccine 2011
City of event: Bangkok, Thailand
Date of event: 12/09/2011
End date: 16/09/2011
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation



- 51** **Title of the work:** Genetic Characterisation of HIV Infection
Name of the conference: XIII Conferencia Española y III Encuentro Iberoamericano de Biometría CEIB2011
City of event: Barcelona, Catalonia, Spain
Date of event: 09/09/2011
End date: 09/09/2011
Organising entity: CEIB
S Pérez-Álvarez; C Brander.
- 52** **Title of the work:** Poster: Genome-Wide Analysis Links Complex Viral Escape from CD8+ T-cell Responses with Control of HCV Infection
Name of the conference: 18th International Symposium on Hepatitis C and Related Viruses
City of event: Seattle, United States of America
Date of event: 08/09/2011
End date: 08/09/2011
Organising entity: European Association for the Study of the Liver
Type of entity: Associations and Groups
- 53** **Title of the work:** Poster: Stress is a Strong Predictor of Elevated Levels of IL-6 in HIV-Infected, HAART-treated individuals.
Name of the conference: International AIDS Society Meeting 2011
City of event: Roma, Italy
Date of event: 18/07/2011
End date: 18/07/2011
Organising entity: International AIDS Society
Type of entity: Associations and Groups
- 54** **Title of the work:** Human Immunodeficiency Virus vaccines
Name of the conference: EUROPRRSNET
City of event: Barcelona, Catalonia, Spain
Date of event: 10/06/2011
End date: 10/06/2011
Organising entity: EUROPRRSNET
C Brander.
- 55** **Title of the work:** Poster: Optimal variable selection for regression models
Name of the conference: Eastern Mediterranean region, 6th EMR-IBS conference
City of event: Creta, Greece
Date of event: 09/05/2011
End date: 09/05/2011
Organising entity: EMR-IBS
Type of entity: Associations and Groups
- 56** **Title of the work:** Poster: Functionally avid cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes are associated with relative control of HIV replication
Name of the conference: Keystone Symposium
City of event: Keystone, United States of America
Date of event: 30/03/2011
End date: 30/03/2011
Organising entity: Keystone Symposia on Molecular and Cellular Biology
Type of entity: Associations and Groups



- 57** **Title of the work:** Poster: Rapid Progression to AIDS is characterized by the absence of CD8+ T-cell HIV specific responses in HIV infected subjects
Name of the conference: Keystone Symposium on HIV Evolution, Genomics and Pathogenesis
City of event: Whistler Mountain, Canada
Date of event: 23/03/2011
End date: 23/03/2011
Organising entity: Keystone Symposia on Molecular **Type of entity:** Associations and Groups and Cellular Biology
- 58** **Title of the work:** Poster: Cytokine profiles during primary HIV-1 infection may predict the clinical outcome and the rate of progression of HIV-infected individuals
Name of the conference: Keystone Symposium on HIV Evolution, Genomics and Pathogenesis
City of event: Whistler Mountain, Canada
Date of event: 21/03/2011
End date: 21/03/2011
Organising entity: Keystone Symposia on Molecular **Type of entity:** Associations and Groups and Cellular Biology
- 59** **Title of the work:** Poster: CTL Epitope Cross-reactivity as a Crucial Factor for the Control of Highly Variable Pathogens
Name of the conference: CROI 2011
City of event: Boston, United States of America
Date of event: 02/03/2011
End date: 02/03/2011
Organising entity: CROI **Type of entity:** Associations and Groups
- 60** **Title of the work:** Poster: Strong Immune Response after Superinfection in a HIV-1 Elite Suppressor Patient
Name of the conference: CROI 2011
City of event: Boston, United States of America
Date of event: 01/03/2011
End date: 01/03/2011
Organising entity: CROI **Type of entity:** Associations and Groups
- 61** **Title of the work:** A Global AIDS Vaccine Based on Conserved Elements of the Viral Proteome
Name of the conference: CROI 2011
City of event: Boston, United States of America
Date of event: 28/02/2011
End date: 28/02/2011
Organising entity: CROI **Type of entity:** Associations and Groups
C Brander.
- 62** **Title of the work:** A Global AIDS Vaccine Based on Conserved Elements of the Viral Proteome
Name of the conference: HIV Vaccine meeting 2010
City of event: Atlanta, United States of America
Date of event: 01/10/2010
End date: 01/10/2010
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation
C Brander.



- 63** **Title of the work:** Poster: HLA class I alleles associated with relative in vivo control of HIV confer intrinsically superior epitope variant recognition than non-beneficial class I alleles
Name of the conference: HIV Vaccine meeting 2010
City of event: Atlanta, United States of America
Date of event: 01/10/2010
End date: 01/10/2010
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation
- 64** **Title of the work:** Poster: Impact of HLA class I-associated selection pressures on HIV-1 accessory and envelope proteins at the population level
Name of the conference: HIV Vaccine meeting 2010
City of event: Atlanta, United States of America
Date of event: 30/09/2010
End date: 30/09/2010
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation
- 65** **Title of the work:** Poster: Relative protection of HIV replication in vivo is mediated by HLA class I alleles that confer intrinsically superior epitope variant recognition
Name of the conference: HIV Vaccine meeting 2010
City of event: Atlanta, United States of America
Date of event: 30/09/2010
End date: 30/09/2010
Organising entity: Global HIV Vaccine Enterprise **Type of entity:** Foundation
- 66** **Title of the work:** Poster: Efficient blockade of the HLA-B27 / TCR interaction by eEnzymatically stable synthetic β and α/β -peptidomimetics
Name of the conference: Swiss Immunology Annual Society Meeting
Date of event: 15/04/2010
End date: 15/04/2010
Organising entity: Swiss Immunology Annual Society **Type of entity:** Associations and Groups
City organizing entity: Geneva,
- 67** **Title of the work:** Rational design of T cell immunogen sequences
Name of the conference: 19th Mexican Immunology Society Meeting
City of event: Cancun, Mexico
Date of event: 12/03/2010
End date: 12/03/2010
Organising entity: Mexican Immunology Society **Type of entity:** Associations and Groups
C Brander.
- 68** **Title of the work:** Role of host and viral genetics of HIV pathogenesis
Name of the conference: Latin American AIDS Research and Training Program Workshop
City of event: Lima, Peru
Date of event: 25/02/2010
End date: 25/02/2010
Organising entity: Latin American AIDS Research and Training Program **Type of entity:** Associations and Groups
C Brander.



- 69** **Title of the work:** Rational Design of broadly protective HIV T cell immunogens
Name of the conference: International AIDS Vaccine Initiative (IAVI)
Date of event: 24/02/2010
End date: 24/02/2010
Organising entity: International AIDS Vaccine Initiative (IAVI) **Type of entity:** Associations and Groups
City organizing entity: Nueva York, United States of America
C Brander.
- 70** **Title of the work:** Oral Communication: Conserved Elements Vaccine for HIV-1 p24gag is immunogenic in mice and macaques
Name of the conference: CROI 2010
City of event: San Francisco, United States of America
Date of event: 18/02/2010
End date: 18/02/2010
Organising entity: CROI **Type of entity:** Associations and Groups
C Brander.
- 71** **Title of the work:** Poster presentation: CTL responses to HIV Gag p24 can be detected in HIV non-controllers but are of low functional avidity, lack cross-reactivity potential and show slow in-vitro response rates to antigen stimulus
Name of the conference: CROI 2010
City of event: San Francisco, United States of America
Date of event: 18/02/2010
End date: 18/02/2010
Organising entity: CROI **Type of entity:** Associations and Groups
C Brander.
- 72** **Title of the work:** Advances in Therapeutic HIV Vaccine Development
Name of the conference: Vaccine Technology VIII
Type of event: Conference
Type of participation: Participatory - Plenary session **Reasons for participation:** Upon invitation
Corresponding author: Yes
City of event: Sitges, Catalonia, Spain
Organising entity: Engineering Conferences International

R&D management and participation in scientific committees

Scientific, technical and/or assessment committees

- 1** **Committee title:** Scientific Advisory Committee PEACHI Consortium
Affiliation entity: University of Oxford
City affiliation entity: Oxford, United Kingdom
Start-End date: 12/07/2017 - 14/07/2017
- 2** **Committee title:** Scientific Advisory Committee GREAT consortium
Affiliation entity: University of Oxford
City affiliation entity: Oxford, United Kingdom
Start-End date: 07/07/2017 - 07/07/2017



- 3** **Committee title:** Ontario HIV Treatment Network, Study section
City affiliation entity: Canada
Start-End date: 2004 - 2006
- 4** **Committee title:** American Association of Immunologists
Start date: 2006
- 5** **Committee title:** Associazione Italiana per la Ricerca sul Cancro, Italy, Study section
City affiliation entity: Italy
Start date: 2005
- 6** **Committee title:** Canadian Institutes of Health Research, Study Section
City affiliation entity: Canada
Start date: 2005
- 7** **Committee title:** NIH / NIAID ZZR-1 Study section
Affiliation entity: NIH/NIAID
City affiliation entity: United States of America
Start date: 2005
- 8** **Committee title:** International AIDS Society
Start date: 2004
- 9** **Committee title:** University of Cape Town, Medical Research Council, South Africa
City affiliation entity: South African Republic
Start date: 2004
- 10** **Committee title:** Mass. General Hospital Interim Support Fund, Study section
Affiliation entity: Mass. General Hospital **Type of entity:** Healthcare Institutions
City affiliation entity: Boston, United States of America
Start date: 2003
- 11** **Committee title:** Mass. General Hospital PEW Scholars Fund, Study section
Affiliation entity: Mass. General Hospital **Type of entity:** Healthcare Institutions
City affiliation entity: United States of America
Start date: 2003
- 12** **Committee title:** Swiss Society for Cellular Biology
City affiliation entity: Switzerland
Start date: 1993
- 13** **Committee title:** Union of Swiss Societies for Experimental Biology
City affiliation entity: Switzerland
Start date: 1993
- 14** **Committee title:** Swiss Society of Immunology and Allergy
Start date: 1992



- 15** **Committee title:** University of Washington, Center for AIDS Research, Study section
Affiliation entity: University of Washington, Center for AIDS Research
City affiliation entity: 2004, United States of America

Other achievements

Stays in public or private R&D centres

- 1** **Entity:** Harvard Medical School **Type of entity:** University
City of entity: Boston, United States of America
Start-End date: 2006 - 2011
Goals of the stay: Contracted
Provable tasks: Profesor Asociado de Medicina
- 2** **Entity:** Massachusetts General Hospital **Type of entity:** Healthcare Institutions
City of entity: Boston, United States of America
Start-End date: 2006 - 2011
Goals of the stay: Contracted
Provable tasks: Adjunto en Inmunología
- 3** **Entity:** Harvard Medical School, Boston **Type of entity:** University
City of entity: Boston, United States of America
Start-End date: 2001 - 2006
Goals of the stay: Contracted
Provable tasks: Profesor Asistente de Medicina
- 4** **Entity:** Massachusetts General Hospital **Type of entity:** Healthcare Institutions
City of entity: Boston, United States of America
Start-End date: 1998 - 2006
Goals of the stay: Contracted
Provable tasks: Asistente en Inmunología
- 5** **Entity:** Harvard Medical School **Type of entity:** University
City of entity: Boston, United States of America
Start-End date: 1998 - 2001
Goals of the stay: Contracted
Provable tasks: Profesor Auxiliar en Medicina
- 6** **Entity:** Harvard Medical School **Type of entity:** University
City of entity: Boston, United States of America
Start-End date: 1995 - 1998
Goals of the stay: Post-doctoral
Provable tasks: Investigador